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Abstract
Congenital heart disease (CHD) is the most common birth defect in infants.
Identifying factors that are critical to embryonic heart development or CHDs in general
could further our understanding of the disease and may lead to new strategies of its
prevention and treatment. Endothelial nitric oxide synthase (NOS3/eNOS) is known for
many important biological functions including vasodilation, vascular homeostasis and
angiogenesis. Previous studies have shown that deficiency in NOS3 results in congenital
septal defects, cardiac hypertrophy and postnatal heart failure. In addition, NOS3 is
pivotal to morphogenesis of aortic valve and myocardial capillary development. The aim
of my thesis was to investigate the role of NOS3 in the embryonic and adult heart. I
discovered that NOS3 deficiency resulted in coronary artery hypoplasia in fetal mice and
spontaneous myocardial infarction in postnatal hearts. Coronary artery diameters, vessel
density and volume were significantly decreased in NOS3-/- mice at postnatal day 0. Lack
of NOS3 also down-regulated the expression of Gata4, Wilms tumor-1, vascular
endothelial growth factor, basic fibroblast growth factor and erythropoietin in the
embryonic heart at E12.5, and inhibited migration of epicardial cells into the myocardium.
In addition, my data show that the overall size and length of mitral and tricuspid valves
were decreased in NOS3-/- compared with WT mice. Echocardiographic assessment
showed significant regurgitation of mitral and tricuspid valves during systole in NOS3-/mice. Immunostaining of Snail1 was performed in the embryonic heart. Snail1 positive
and total mesenchymal cells in the AV cushion were decreased in NOS3-/- compared with
WT mice at E10.5 and E12.5. Finally, in the adult aortic valves, NOS3 is important in
inhibition of thrombosis formation. Deficiency in NOS3 leads to aortic valve thrombosis
ii

and calcification. At 12 months old, 72% (13/18) of NOS3-/- mice showed severe
spontaneous aortic valve thrombosis compared with WT mice (0/12). Ex vivo culture of
aortic valves showed that platelet aggregation and adhesion were significantly increased
in NOS3-/- aortic valves compared with WT aortic valves. There was also a significant
-/-

regurgitation of the aortic valve during systole in the NOS3 compared with WT mice. In
addition, NOS3 deficiency resulted in significant aortic valve stenosis, calcification and
fibrosis. In summary, these data suggest NOS3 plays a critical role in embryonic heart
development and morphogenesis of coronary arteries and inhibits thrombosis formation
in the adult aortic valves.
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CHAPTER 1

Literature Review
1.1

Congenital Heart Disease
Congenital heart disease refers to a defect in the structure of the heart and/or

vessels present at birth. This defect, however, can be detected earlier by prenatal
diagnosis such as fetal echocardiography. The disease affects up to 5% of people of the
general population and is the leading cause of death in infants during the first year of life in
the industrialized countries.1, 2 It is estimated that 96,000 adults in Canada have congenital
heart disease.3 These patients have increased risk of arrhythmia, bacterial endocarditis and
heart failure later in life.4 Thus, congenital heart disease is a major cause of mortality and
morbidity in both infants and adults. The cause of congenital heart disease may be either
genetic or environmental, but is usually a combination of both. It is estimated that only 15%
of all congenital heart disease can be traced to a known cause.4 Some genetic factors have
been linked to cause congenital heart disease, while the majority of factors are still unknown.
Thus understanding the mechanisms that regulate the formation of the heart and the
coronary artery system could further our understanding of the disease and lead to new
strategies of its prevention or treatment.
1.2

Valvular Heart Disease
Valvular heart disease is a significant health problem and contributes to more than

44,000 deaths in United States annually.5 The causes of valvular heart disease include
congenital malformations such as bicuspid aortic valves and rheumatic disease which is
secondary to bacterial infection. Congenital valve disease affects about 2% of the general
1

population.6, 7 More specifically, bicuspid aortic valve disease is the most common
congenital heart defect.8-10 As the name suggests, the bicuspid aortic valve is typically
made of 2 unequal-sized leaflets rather than the normal three. Bicuspid aortic valve
disease is often asymptomatic during childhood. In adulthood, complications commonly
arise and the burden of disease from bicuspid aortic valve disease is more significant than
any other congenital heart disease. Despite this heavy economic burden, our
understanding of bicuspid aortic valve disease is limited. Incidence of valvular heart
disease dramatically increases to more than 13.3% over the age of 75.11, 12 The disease
may manifest as valvular stenosis, an obstruction of outflow, or as regurgitation, a
defective closure resulting in backward flow. Congenital valve malformations tend to
cluster in families among both close and distant relatives, suggesting a genetic
component to this disease.13, 14 However, underlying molecular mechanisms responsible
for congenital valve disease are still not fully understood.
1.3

Hypoplastic Coronary Artery Disease
Congenital coronary anomalies affect up to 5% of the general population.15, 16 Most

of them are asymptomatic and therefore often unrecognized. However, people with major
congenital coronary artery malformation are at greater risk for myocardial ischemia,
infarction and sudden cardiac death.17 Hypoplastic coronary artery disease (HCAD) is a rare
congenital coronary abnormality. It is characterized by malformation of one or more major
branches of the coronary arteries with a marked decrease in luminal diameter and length.18-20
HCAD can be asymptomatic, but it can be associated with myocardial infarction and sudden
cardiac death under stress, usually in the form of intense physical activity.17, 21 However, the
molecular mechanisms responsible for development of HCAD remain unclear.
2

1.4

Formation of the Four-Chambered Heart
Heart development is a complex process involving many coordinated processes

including, migration, differentiation and proliferation of cardiac progenitors. The cardiac
progenitors are derived from three distinct origins: the anterior lateral plate mesoderm or the
primary heart field; the second heart field which is located dorsal and anterior to the primary
heart field; and the cardiac neural crest from the dorsal neural tube.22-24 In addition, the
epicardium is also a source of cardiac progenitors which give rise to coronary arteries and
possibly cardiomyocytes.24, 25 Cardiac morphogenesis starts from the fusion of the 2 patches
of anterior lateral plate mesoderm to form the cardiac crescent at embryonic day (E) 7.5 in
the mouse embryo.26 By E8 the primitive heart (or heart tube) is formed. As the heart tube
forms, cells from the second heart field migrate into the dorsal aspect to the heart tube in the
pharyngeal mesoderm. Upon rightward looping of the heart tube, they cross the pharyngeal
mesoderm and populate the outflow tract with contributions also from the cardiac neural
crest. As the heart develops, the primitive heart undergoes specification processes including
chamber specification, septation and trabeculation. The atrial and ventricular septum starts
to form at E10. Multiple primordia contribute to a central mesenchymal mass, including the
mesenchyme on the leading edge of the primary atrial septum, the atrioventricular
endocardial cushions, and the cap of mesenchyme on the spina vestibule.27, 28 Fusion of
these components closes the ostium primum, completing atrial and atrioventricular septation.
The mitral and tricuspid valves are derived from the endocardial cushion while the aortic
and pulmonary valves are formed from endocardial cushions and with a contribution of
neural crest cells.29 The formation of atrioventricular septum and valves is tightly regulated
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by coordinated cell proliferation, apoptosis and remodelling. By E14.5, a fully functional
four-chambered heart is formed in mice.26
1.5

Formation of the Coronary Arteries
The development of the coronary vessels is an important event at the later stages of

cardiogenesis. Coronary development starts at E9.5 in mice from proepicardial organ (PEO)
located at the pericardial surface of the septum transversum close to the sinus venosus.30, 31
Cells from PEO migrate and spread over the surface of the myocardium to become the
epicardium. Concurrent with formation of the epithelium, some epithelial cells migrate
further into the subepicardial space and undergo epithelial-mesenchymal transition (EMT)
to become mesenchymal cells, which migrate throughout the developing myocardium and
give rise to vascular smooth muscle cells, fibroblasts and possibly endothelial cells, and
form coronary vasculature of the heart. The proximal ends of the coronary arteries connect
to the ascending aorta through coronary orifices at the level of the left and right sinuses of
the semilunar valves. Coronary veins connect to the right atrium via the coronary sinus. By
E15.5, a complete coronary vascular system is established.30, 31 Over the past decade, many
factors have been shown to be crucial in the formation of the coronary arteries,30, 32 but the
role of NOS3 in this process is still not well understood.
1.6

Atrioventricular Valve Development
The atrioventricular (AV) valve development starts at E9 with the formation of

endocardial cushions. A subpopulation of endocardial cells of the endocardial cushion
undergoes endothelial-to-mesenchymal transition (EndMT) and provides the primary cell
source for the development of AV valves.33 Proliferation of the mesenchymal cells and
matrix deposition extend the cushions into the cardiac lumen and form primordia of each
4

distinct valve. This is followed by elongation and remodeling of the valve primordia,
which leads to the gradual maturation of valves by E15.34 EndMT is a crucial process for
proper formation of AV valves.35 Transforming growth factor (Tgfβ), bone
morphogenetic protein (Bmp)-2, and Snail1 have been shown to promote EndMT and
valve formation.36 In addition, Notch-dependent NOS3 activation has been shown to
promote EndMT in the developing atrioventricular (AV) canal from E9 to E11.5 via
activation of the PI3-kinase/Akt pathway.37
1.7

Factors in Heart Development
The formation of the heart is highly regulated and complex in nature. Studies have

shown both environmental and genetic factors play a crucial role in heart development.38
Well known environmental factors such as drug abuse, alcohol abuse and maternal
diabetes all have been linked to as risk factors for congenital heart disease.39 In addition,
several lines of evidence also support a genetic contribution to congenital heart disease.40,
41

Over the past 50 years, through the use of genetically modified animals various factors

have been identified to govern different aspects of heart development. In 2003, the
completion of the human genome project allowed us to further test the importance of
these factors in humans through the use of gene sequencing. These factors can be
grouped into 2 categories: first, transcription factors that are responsible for initiating and
regulating heart development and second, growth factors that acts as effectors to guide
heart development.
1.7.1 Transcription Factors in Heart Development
Gata4 has been shown to be crucial in both human and murine heart
development.42, 43 Interestingly, Gata4 is one of the earliest transcription factors
5

expressed in the developing heart.44 More specifically, Gata4 mRNA can be detected as
early as E7.0 in the pre-cardiac mesoderm and during formation and bending of the heart
tube in endocardium, myocardium and pre-cardiac mesoderm at E8.0.44 It is worth noting
that abundant Gata4 continues to be expressed in the heart throughout adulthood.
Transgenic mice with inactivation of the Gata4 gene die during embryonic development
due to the failure of ventral morphogenesis and heart tube formation between E8.0E9.0.45, 46 In addition, functional mutation of GATA4 in humans has been linked to
congenital heart disease.47 Together, as a master regulator of cardiogenesis, Gata4 is
required during embryonic heart development in both mice and humans.
Nkx2.5, a direct binding partner of Gata4 through its homeodomain, has also been
shown to be involved in early heart development.48, 49 As one of the earliest identified
factors associated with human congenital heart disease, Nkx2.5 has been studied quite
extensively throughout different organisms.50-53 Mutations have been identified in
patients with a variety of congenital heart malformations including septal defects,
conotruncal abnormalities, and atrioventricular conduction defects. Similar to Gata4,
Nkx2.5 is also expressed early during heart development.54 Nkx2.5 is thought to act
together with Gata4 to control the complex and precise regulation of heart development.
Heart development involves the precise looping and formation of the heart
chambers, the development of the cardiac conduction system as well as the coronary
vascular system. Wilm’s tumor -1 (Wt1) is a transcription factor that is involved in the
formation of the coronary vasculature system. Wt1 has been shown to regulates
epicardial epithelial to mesenchymal transition (EMT), a process which is required for
coronary artery formation.55, 56 Wt1 regulates epicardial EMT and heart development
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through multiple signaling pathways. It has been shown Wt1 promotes canonical Wnt/βcatenin signaling and Raldh2, a regulator of retinoic acid signaling.55, 56 By controlling
epicardial EMT, Wt1 directs the coronary vasculature development in the heart.
Snail1, a zinc finger transcriptional repressor, has been studied extensively in
developmental EMT. Mice with conditional knockout of Snail1 form a mesodermal layer
with distinctly epithelial characteristics and die early in gastrulation around E7.5.57 Snail1
is also required for EMT-mediated mesoderm formation in zebrafish and for neural crest
cell migration in mice.58 EMT is a crucial process during heart development which
contributes to coronary artery formation, valve formation and septation of the ventricles
and atria.59, 60 Taken together, the role of Snail1 in EMT and the importance of EMT in
heart development, Snail1 dictates the proper formation of the heart by regulating EMT.
The transcription factors listed above are factors investigated in the current thesis,
but this only represents the tip of the iceberg, as the majority of the transcription factors
that are important during various aspects of heart development are beyond the scope of
this thesis. Other transcription factors that are notable include Tbx5, Mef2C, NFATc1
and Pitx2. Txb5 is a T-box containing transcription factor, that is expressed early in heart
development at E8.0.61 TBX5 deficiency in humans results in Holt-Oram syndrome, a
condition inherited as autosomal dominant , and the range of cardiac abnormalities
include atrioventricular blocks, failure of septa formation and hypoplastic left heart
syndrome, aortic stenosis, mitral valve prolapse, and the tetralogy of Fallot.62 Mef2C is a
member of the myocyte-specific enhancer factor 2 (Mef2) family of transcription factors
and is also important for cardiac muscle formation.63 In addition, recent discoveries
reveal the specific role of Mef2C in second heart field development. Mef2C drives the
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development of the right ventricle, septum formation and contributes to the proper
development of the atria, the outflow tract, pulmonary and aortic valves and endothelial
cells in the coronary artery.64 Specific deletion of Mef2C in the heart results in right
ventricle defects as well failure of the heart tube to undergo looping morphogenesis.65
NFATc1, a transcription factor required for heart valve formation in mice, starts to be
expressed early during murine heart development around E8.5.66, 67 Specific deletion of
NFATc1 in the hearts results in complete absence of pulmonary and aortic valves, leading
to congestive heart failure and death of the animal between E13.5-E17.5.67 Finally, Pitx2
is a crucial transcription factor in early heart development as it is responsible for the
establishment of left-right symmetry.68 PITX2 mutations in humans result in varies
complex syndromes such as Axenfeld-Rieger syndrome (ARS), iridogoniodysgenesis
syndrome (IGDS), and sporadic cases of anterior segment mesenchymal dysgenesis.69-71
1.7.2 Growth Factors in Heart Development
Growth factor signalling is a crucial component in heart development. It provides
the local niche for the migration and expansion of cardiomyocytes and other precursors in
the heart. Many growth factors have been identified, via mainly genetically modified
animals, to provide fundamental insights into their role in heart development. More
specifically, growth factors in the heart can acts as a chemokine that attracts precursors in
the epicardium to migrate into the myocardium and form coronary vasculature32 Without
the proper guidance provided by the local growth factors, coronary vasculature cannot be
correctly formed.
Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)
have been shown to the crucial in coronary artery formation. More specifically, inhibition
8

of VEGF and FGF decreases capillary formation and arterial growth.30, 32, 72 During early
stages of coronary artery development, the expression FGF is high throughout the
myocardium and VEGF expression is locally high at the site of early vascular tube
formation.73, 74 It is worth noting that both factors have the potential to stimulate vascular
growth in the embryonic heart.75 Myocardium specific overexpression of Fgf increases
coronary artery density and branching, while Vegf conditional knockout impairs the
recovery of coronary vessels from ischemic injury in mice.76, 77 Interestingly, the arterial
diameter can be increased via the administration of anti-FGF-2 and anti-VEGF
antibodies.78 These data suggest VEGF and FGF are crucial growth factors that is
required during coronary artery formation.
Erythropoietin (EPO) is known for its vital role in the formation of red blood cells
by binding to its receptor (EPOR).79 Through the use of genetically modified animal, Epo
signalling through its receptor Epor was shown to be crucial in embryonic coronary
artery formation. Epor is expressed in the epicardium and pericardium of the developing
heart from E10 to E14. In Epor knockout mouse embryos, the epicardium was thin and
detached from the myocardium. In addition, the coronary vessel network was severely
affected with disorganized structures.79 This shows that inactivation of the Epo pathway
leads to decreased epicardial precursors, and the detachment of the epicardium from the
myocardium inhibited the crucial EMT process that is required for coronary artery
formation.
1.8

Endothelial Activation and Thrombosis Formation
Endothelial activation generally refers to endothelial dysfunction or damage

which may eventually contribute to vascular disease or thrombosis formation. Endothelial
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activation represents a change in phenotype of the endothelial cells from the quiescent
state towards a state that involves host defense response.80, 81 Most cardiovascular risk
factors activate the endothelium which results in expression of chemokines, cytokines,
and adhesion molecules that interact with the immune system to target inflammation to
damaged tissues.80, 81 The molecular change involved in endothelial activation is
switching from NO-mediated cellular processes, such as cGMP signalling or snitrosylation, to the activation of ROS signalling.82 This process is largely mediated by
the uncoupling of NOS.83 Uncoupling of NOS3 is related to the depletion of important
cofactor BH4, phosphorylation of specific residues of NOS3, mainly on residues serine
114, threonine 495, serine 615, serine 633 and serine 1177, increased S-glutathionylation
and increased production of peroxynitrite.83, 84 NOS3 ROS production deteriorates
cellular function via phosphorylation of transcription factors, induces adhesion molecule
production and protease activation. Endothelial activation and ROS production can be a
part of the normal host defense. It is when this process is extended, prolonged and/or in
combination of the pro-inflammatory stimuli that results in endothelial damage.85 The
damaged endothelium then contributes to vascular disease such as atherosclerosis or
thrombosis formation.
Endothelium integrity not only depends on the extent of injury, but also on the
ability of the endogenous capacity to repair.86 Repair mechanisms mainly occur in two
ways. First is the replication of the mature endothelial cells which replaces the lost and
damaged cells. Second is recruitment of circulating progenitor cells. These cells originate
from the bone marrow and upon injury can be recruited to the site of injury to
differentiate into endothelial cells.87, 88 Mobilization of these cells is in part NO10

dependent. Factors that have been shown to improve endothelial function and NO
bioavailability such as statins and exercise have also been shown to promote endothelial
progenitor cell mobilization.89-91 Therefore, it is a balance of repair and extent of
endothelial damage that ultimately determines the integrity of the endothelium.
Endothelial activation and damage, if unresolved, may result in thrombosis formation and
vascular disease.
Arterial and venous thrombosis and thrombus embolization can be life threatening
and if left untreated may lead to death. Arterial and venous thrombosis are blood clots
that are formed in arteries and veins. The arterial clot is predominantly caused by
platelets aggregation while a venous thrombus is mainly composed of fibrin and red
blood cells and variable amount of platelets and white cells.92-94 Thrombi can occlude
vessels locally at the site of formation or travel to other organs through blood and cause
occlusion in distal vessels. Occlusions in the brain or the heart are especially dangerous
and can cause stroke or heart attacks. However, thrombi may be spontaneously formed
and lysed by local conversion of plasminogen to plasmin, a proteolytic enzyme which
degrades plasma fibrinogen.95 The dynamics of platelet deposition and thrombus
formation are modulated by the type of injury and the local geometry at the site of
damage.92-94 Arterial thrombosis formation involves 3 distinct steps. First, platelets
adhere at the recognition sites and are activated by the thromboactive substrates. The
second step involves platelets spreading on the surface of attachment. Finally, platelets
aggregate with each other to form a platelet plug. This process greatly depends on the
efficiency of platelet recruitment and local geometry. Once platelets aggregate, other
blood cells are recruited such as red blood cells, neutrophils and sometimes monocytes.9211

94

The formation of a thrombus on the heart valve usually involves prosthetic valves. The

process of thrombus formation is initiated during heart valve replacement surgery. The
damaged peri-valvular tissue and prosthetic materials activate platelets as soon as blood
starts flowing across the prosthetic valve. This results in the immediate deposition of
platelets. In addition, the abnormal hemodynamic characteristics of mechanical prosthetic
devices promote platelet activation.96-99 It is worth noting that bioprosthetic valves made
from animals such as pig are considerably less thrombogenic mainly because of the
biological properties of materials used in their construction.96-99 The spontaneous
formation of a thrombus on the aortic valve is extremely rare in humans with only less
than a dozen of case reports in the literature.100-109 However, aortic valve thrombosis is
extremely dangerous, as it could lead to embolization, and subsequent cerebrovascular
events such as stroke, myocardial infarction and death.101-104, 108 Surgery is the only
available treatment for these patients. Anti-coagulant therapy is still under debate as to
whether the beneficial effects outweigh the deleterious effects.100 To our knowledge,
spontaneous aortic valve thrombosis has never been studied in animal models.
1.9

Aortic Valve Calcification
Calcific aortic valve stenosis (CAVS) is the most common valvular disease.11

CAVS is characterized by progressive narrowing of the aortic valve resulting in aortic
stenosis, calcification and thickening of the aortic valves and aortic valve regurgitation.110
Traditionally, calcified aortic valve stenosis has been associated with normal aging and
valve degeneration. However, recent studies suggest that CAVS can be attributed to a
genetic origin. Mutations in Notch1, an important factor that is involved in many
developmental processes, has been shown to cause aortic valve disease similar to
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CAVS.111 Notch1 functions by repressing the activities of Runx2, a central transcriptional
regulator in osteoblast cell fate.111 The origin of calcification in the aortic valve is still
under debate. Studies have shown that calcification originates from circulating progenitor
cells that would reside on the aortic valve and differentiate into bone marrow–derived
type I collagen+ osteocalcin (OCN)+ CD45+ subpopulation of mononuclear adherent cells,
these cells then cause ossification.112, 113 Another hypothesis is that valvular interstitial
cells undergo differentiation and they would gain an osteoblast-like phenotype and cause
calcification.114, 115 It is likely a contribution of both scenarios that result in valve
calcification. Environmental influences may also play a role in CAVS. Cardiovascular
risk factors such as smoking, hypercholesterolemia, hypertriglyceridemia, diabetes
mellitus, and chronic kidney disease all have been shown to contribute to CAVS.116
Currently, the only clinical treatment for CAVS is valve replacement surgery. Effective
medical treatments to alter the course of CAVS are non-existent.
1.10

Nitric Oxide Synthase
Nitric oxide (NO) is produced from the guanidino group of L-arginine in an

NADPH-dependent reaction catalyzed by a family of NO synthase (NOS) enzymes in living
organisms.117, 118 Originally identified as a vasodilatory agent, NO is now recognized as an
important signalling molecule involved in a wide range of physiological and
pathophysiological processes including cell growth, apoptosis, antithrombosis,
neurotransmission, and immunological regulation.118, 119 The wide range of functions and
physiological importance of NO were recognized by the Nobel committee and awarded the
1998 Nobel prize of medicine to Drs. Furchgott, Ignarro and Murad for their contributions
towards the discovery of NO. The vasodilatory function of NO was first discovered by Dr.
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Furchgott and was termed endothelium-derived relaxing factor (EDRF).120 Later on, EDRF
was identified as NO by Dr. Ignarro.121 The ultimate signalling of NO through cGMP was
shown by Dr. Murad.122 There are 3 distinct isoforms of NOS: neuronal NOS (NOS1),
inducible NOS (NOS2) and NOS3. Each NOS isoform is encoded by a distinct gene and is
expressed in a variety of tissues and cell types. NO produced from NOS1 and NOS3 is
involved in intracellular and intercellular signalling, whereas the high output NO produced
by NOS2 is associated with inflammatory processes.118, 119 NO produced by different
isoforms of NOS contributes towards signalling in the neuronal, immune, reproductive,
vascular and most importantly, cardiovascular systems.118, 119 Shear stress induces NOS3
expression in the cardiovascular system during chick embryonic development.123 In addition
to shear stress, NOS3 can also be induced and activated by Krüppel-like factor 2 (Klf2), an
endothelial transcription factor that is crucially involved in vasculogenesis.124, 125 In the
adult heart, NO released from NOS3 has several major roles including coronary
vasodilation and tonic inhibition of mitochondrial O2 consumption.118, 126 NO may also play
a role in the muscarinic-cholinergic inhibition of -adrenergic-stimulated chronotropy,127
inotropy,126 and atrioventricular nodal conduction. The effects of NO are mediated by the
cGMP-dependent signaling and protein modification through S-nitrosylation.118, 128 In
cGMP-dependent signalling, NO would activate downstream guanylate cyclase which leads
to the production of cGMP. Binding of cGMP to the regulator domain of protein kinase G or
cGMP dependent protein kinase induces a conformation change which stops the inhibition
of catalytic core and allows phosphorylation of other downstream proteins. Protein kinase
G is a serine/threonine-specific protein kinase that phosphorylates a number of important
biological targets. 118, 119 These targets drive many cellular processes which may regulate
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smooth muscle relaxation, platelet function, sperm metabolism, cell division and nucleic
acid synthesis. Other NO mediated signalling includes S-nitrosylation. This is defined by the
process of covalent incorporation of NO into thiol groups forming S-nitrosoprotein (SNO).
118, 125

This modification allows activation or deactivation of proteins. The activation or

deactivation of proteins depends on the type of protein. For example, caspases that are
important in cellular apoptosis have been shown to be inhibited by SNO. On the other hand,
metalloproteinases which are important in degrading extracellular proteins are activated by
SNO. SNO is an extremely complex process which remains poorly understood.
1.11

NOS3 Expression in the Embryonic Heart
NOS3 is expressed in the heart early during mammalian embryonic development.

129,130

Although this expression is not restricted in the heart, other organs such as lung,

liver, gastrointestinal tract, reproductive organs and brain hippocampus all have NOS3
expression. Immunohistochemical analysis in mice using NOS3 specific antibodies
revealed that the heart, including cardiomyocytes, start to express NOS3 at E9.5 and
expression remains high up to E13.5. Starting from E14.5, levels of NOS3 expression
decrease in both atria and ventricles. After E19.5 low NOS3 levels are still detectable and
this level of NOS3 expression in the myocardium remains to adulthood.130 Parallel with
NOS expression, there are also changes in guanylate cyclase and cGMP production
indicating the NO-cGMP signaling pathway in the heart development. The production of
NO from NOS3 regulates the voltage-dependent L-type Ca2+ current in cardiomyocytes
during early embryonic development and has been shown to promote cardiomyogenesis
from mouse embryonic stem cells.130-132 It is important to note that although NOS1 and
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NOS2 are expressed during cardiogenesis, NOS1 and NOS2 knockout mice have normal
cardiac phenotype.
1.12

NOS3 and Heart Development
Septal defects are the most common cardiac malformations in humans.133 However,

the molecular mechanisms that govern the formation of atrial and ventricular septum remain
poorly understood. In recent years, through the use of genetic knockout mice, several
transcriptional factors including Gata4, Nkx2.5 and Tbx5 have been identified to be critical
in the development of atrial and ventricular septum.133, 134 In addition, mutations in these
factors are associated with congenital septal defects in humans.133, 135 Feng et al. show that
deficiency in NOS3 results in congenital septal defects and heart failure, and is accompanied
by 85% postnatal mortality.136 All mortalities occur within the first 7 days after birth. Postmortem examination show NOS3-/- mice have a high incidence of congenital septal defects
with 64% atrial septal defects and 11% ventricular septal defects. Congenital septal defects
can be a result of improper fusion of the atrioventricular cushions during embryonic heart
development. In addition, increases in apoptosis in atrioventricular cushions can also
contribute to congenital septal defects.137, 138 In order to investigate the role of NOS3 in
septal development, myocardial apoptosis was analysed in WT and NOS3-/- hearts at E12.5,
a crucial time point in which the atrioventricular cushions start to fuse together. Feng et al.
show that there is an overall increase in the apoptotic activities in the NOS3-/- compared with
WT hearts as measured by both caspase 3 activity and cytosolic DNA fragments. In order to
determine the apoptotic activity in the atrioventricular cushion, TUNEL staining was used.
Feng and colleagues show that there is a significant increase in the apoptotic activity in the
region of the atrioventricular cushions, which may contribute at least in part to the increased
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incidence of congenital septal defects seen in the postnatal day 1 NOS3-/- mice.136 Low
levels of NO produced by NOS3 inhibit apoptosis via S-nitrosylation of caspase-3, a critical
protease responsible for the execution of apoptosis, and by promoting expressions of
cytoprotective proteins including heme oxygenase-1, heat shock protein 70 (HSP70) and
metallothionein.119 In addition, NO has also been shown to inhibit mitochondrial
cytochrome c release and decrease permeability transition pore opening via mitochondrial
membrane depolarization and inhibition of Ca2+ accumulation.139 These mechanisms may
explain the increased apoptosis in the embryonic heart of NOS3-/- mice.
Many factors may regulate the expression of NOS3 during embryonic heart
development. Bio-informatics analysis of the mouse NOS3 locus showed three canonical
Tbx5 binding sites, two of which are flanked by Gata binding site that binds to both Tbx5
and Gata4 with high affinities.140 Using genetically modified animals, Nadeau et al. showed
that endocardial specific knock-down of Tbx5 results in atrial septal defects with a 100%
penetrance, suggesting Tbx5, a potential upstream regulator of NOS3, is also crucial in the
proper formation of the atrial septum.140 Furthermore, compound haploinsufficiency of
Tbx5 and NOS3 exacerbates the cardiac phenotype caused by deletion of a single Tbx5
allele from endocardial cells, suggesting that NOS3 may be a genetic modifier of Tbx5.140
Interestingly, decreases in enzyme activity and NO production in an 894G>T polymorphism
of the NOS3 gene are associated with increased risks of CHD.141-143 Environmental factors
and maternal conditions including psychological stress, hypertension and diabetes have been
linked to increased risks of congenital heart disease.13 It has been shown that these
environmental and maternal conditions can decrease NOS3 expression and/or activity.144, 145
The finding that NOS3, an enzyme that may be regulated by environmental conditions,
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interacts with Tbx5, suggests the importance of gene–environment interactions in the setting
of congenital heart disease and may help to explain the variable expressivity of the same
mutation among affected family members and the complex inheritance patterns of
congenital heart disease.140, 146
In addition to the congenital septal defect, cardiac hypertrophy is also seen in
NOS3-/- mice at postnatal day 0.136 From gross inspection and quantification, the NOS3-/hearts are significantly larger than WT hearts. In order to determine if the cardiac function is
impaired, in vivo heart shortening was determined in the anesthetized P1 mice using
ultrasound crystals that were placed on the surface of the heart. Feng et al. show that percent
shortening is significantly decreased in NOS3-/- compared to WT hearts. In addition, LV
chamber size is significantly increased in NOS3-/- hearts. Furthermore, severe pulmonary
congestion with focal alveolar edema is also seen in NOS3-/- mice at P1. Cardiac dysfunction
and pulmonary congestion are typical clinical manifestations of heart failure. These results
suggest that the higher mortality in postnatal NOS3-/- mice is likely due to the development
of heart failure after birth.136 However, the exact cause of heart failure remains unclear.
Congenital heart defects and decreased capillary density in the heart and lungs may
contribute to the development of heart failure after birth in NOS3-/- mice.147-150
1.13

NOS3 and Its Upstream Activators
In addition to transcription factors, NOS3 activity and expression are also

regulated by a serine/threonine kinase Akt, also known as protein kinase B (PKB).151-153
Akt is an important mediator of phosphatidylinositol-3 kinase (PI3K) signaling that
regulates a wide variety of cellular functions including survival, growth, proliferation,
glucose uptake, metabolism, and angiogenesis.154 The effects are achieved through the
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regulation of genes and proteins involved in these processes including NOS3.155, 156 There
are three Akt isoforms, Akt1, Akt2 and Akt3, which have similar structures and
molecular sizes (57 kDa). All three Akt isoforms are expressed in the embryo starting
from two-cell stage to virtually every organ during embryonic development. Inhibition of
PI3K or Akt attenuates cardiomyocyte differentiation in embryonic stem cells, suggesting
a critical role of PI3K/Akt signaling in early stage cardiomyocyte differentiation.157 Three
Akt isoforms have similar but yet distinct physiological roles. Targeted disruption of the
Akt1 gene in mice results in growth retardation with 20% reduction in body size as well
as septal defects.158, 159 Akt2 knockout mice display insulin resistance and growth
retardation while Akt3 knockouts show reduced brain size.160, 161 It is worth noting that
the septal defects seen in the Akt1-/- resembles to that of the NOS3-/- mice.136, 158 Akt1-/mice showed perimembranous and muscular ventricular septal defects as well as atrial
septal defects which are similar to those of NOS3-/- mice.
The effect of Akt is mediated in part by upregulation of Gata4 expression via
phosphorylation of Gsk-3.162 Gsk3 inhibits the DNA binding activity of Gata4. Upon
phosphorylation by Akt, Gsk3 exits the nucleus, which curtails the inhibitory effect of
Gsk3 on Gata4, leading to increases in Gata4 activation.162 Gata4 is a transcriptional
factor that belongs to an evolutionarily conserved family of zinc finger-containing proteins,
which has 6 members.163 Gata-1, -2 and -3 are expressed in hematopoietic stem cells while
Gata-4, -5 and -6 are expressed in various mesoderm- and endoderm-derived tissues
including the heart, liver, lung, gonad, and gut. Gata4 is a critical regulator of early
cardiogenesis. Homozygous Gata4 knockout mice die at E9.5 and display defects in heart
and foregut morphogenesis.45 Using tetraploid embryo complementation, Zhao et al. (2008)
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showed that Gata4 controls cardiomyocyte differentiation in mice. It appears that in the
Gata4-/- mice, initiation of cardiomyocyte differentiation starts normally, but progenitors
cannot differentiate into terminal cardiomyocytes as shown by the lack of smooth muscle
actin, myosin heavy chain or sarcomeric actin staining.164 In humans, heritable mutations of
GATA4 result in congenital heart defects including, atrial septal defects, ventricular septal
defects, atrioventricular septal defects, pulmonary valve thickening or insufficiency of
cardiac valves.135 Interestingly, the promoter region of NOS3 contains Gata4 binding
sites.140 Studies have shown that Gata4 binds to these sites and increases NOS3 promoter
activity,165 suggesting Gata4 also serves as an upstream activator of NOS3.
1.14

NOS3 and Its Downstream Effectors
A classic pathway by which NO mediates its biological function is through

cGMP-dependent protein kinase G (PKG) signaling.166 Activation of PKG has been
shown to up-regulate varies downstream transcription factors that are important in heart
development.167, 168 Thus, a deficiency in NOS3 decreases NO and cGMP production, and
may lead to decreased PKG activation and down-regulation of transcription factors in
heart development such as Gata4. Gata4 is a master regulator of heart development, and
controls the expression of many growth factors including VEGF, FGF and EPO, that are
important for coronary vessel formation and heart formation.169-171 NO can exert its
biological effect through other mechanisms. First, NO can cause oxidation of ironcontaining proteins such as ribonucleotide reductase. Ribonucleotide reductase is an
important enzyme in formation of formation of deoxyribonucleotides from
ribonucleotides. In addition, NO can activate proteins via sulfhydryl group
nitrosylation.172 Nitrosylation involves the covalent binding of a nitric oxide into thiol
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groups, to form S-nitrosothiol (SNO). S-nitrosylation has since been shown to be
ubiquitous in biology.173-175 Dysfunction in S-nitrosylation has been associated with
cardiovascular disease, Parkinson's disease, Alzheimer's disease and Amyotrophic Lateral
Sclerosis (ALS). Finally, there is an emerging role of S-nitrosylation in cancer
biology.176-179
1.15

NOS3 Promotes Cardiomyocyte Proliferation
NOS3 is important to cardiomyocyte proliferation during early postnatal cardiac

development.180, 181 To assess proliferation, cardiomyocytes were isolated from neonatal
mice born within 24 hours and cultured for up to 96 hours. Cell proliferation was
determined by bromodeoxyuridine (BrdU) incorporation and cell counts. Lepic et al.
showed that cultured NOS3-/- cardiomyocytes displayed fewer cells and lower BrdU
incorporation compared with WT cardiomyocytes.181 In order to analyze if the decreased
cardiomyocyte proliferation is related to the level of NO produced by NOS3, NOS3-/- and
WT cardiomyocytes were treated with an NO donor and a NOS inhibitor, respectively.
Treatment with the NO donor diethylenetriamine NONOate increased BrdU
incorporation and cell counts in NOS3-/- cardiomyocytes. Inhibition of nitric oxide
synthase activity using NG-nitro-L-arginine methyl ester (L-NAME) decreased the level
of BrdU incorporation and cell counts in WT cardiomyocytes. Furthermore, to investigate
cardiomyocyte proliferation in vivo, neonatal mice were treated with BrdU. Deficiency in
NOS3 significantly decreased BrdU labeling indexes in neonatal hearts.181 These data
suggest that NO production from NOS3 is necessary for postnatal cardiomyocyte
proliferation, providing a crucial role of NOS3 during postnatal heart development.
However, despite decreases in cell proliferation, the overall size of the heart is enlarged
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in NOS3-/- as compared to WT mice (Figure 1A). This is probably due to the fact that
cardiomyocyte proliferation is low and cardiac hypertrophy is the predominant response
during early postnatal heart development.182, 183
1.16

NOS3 Promotes Postnatal Heart Maturation
The fetal and neonatal hearts develop through both hyperplasia and hypertrophy,

which are increases in cell number and cell mass, respectively.183, 184 During early
postnatal cardiac development, proliferation still occurs, albeit at a much lower level
compared to fetal hearts. However, shortly after birth cardiomyocytes undergo
binucleation, accompanied by a cessation of proliferation and a complete switch to
hypertrophic growth.182, 183 In rodents this transition from hyperplastic growth to
hypertrophic growth occurs within approximately 1-2 weeks after birth.182, 183 Embryonic
heart development is characterized by the expression of cardiac specific proteins such as
atrial natriuretic peptide (ANP) and proteins that form the contractile apparatus such as
myosin heavy chain (MHC). After birth, as the heart gradually gains a mature phenotype,
ANP expression is decreased and there is also a switch from beta to alpha isoform of
MHC in cardiomyocytes.185 In the mature myocardium, α-MHC is the predominant
isoform.186, 187 Lepic et al confirmed these postnatal changes in the WT mice and showed
that cardiac ANP expression is progressively decreased from postnatal day 1 to day 7
while the expression of α-MHC is increased.181 On the other hand, in the NOS3-/- hearts,
the levels of ANP remain high and the levels of α-MHC are significantly decreased at
postnatal day 7, suggesting that NOS3 deficiency disturbs the normal temporal changes of
ANP and α-MHC during postnatal heart development. These data support the notion that
NOS3 plays an important role in promoting postnatal heart maturation.181 However, the
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underlying molecular mechanisms responsible for these changes are not fully understood.
Studies have shown that NF-κB, a transcription factor that is involved in inflammation,
cell survival and growth, can modulate the expression of ANP and α-MHC.188, 189 In
addition, NO can increase or decrease the expression of NF-κB depending on its
concentrations and the cell types.190, 191 It is possible that NO produced from NOS3 may
act through the NF-κB pathway to modulate expression of ANP and α-MHC in postnatal
hearts.
1.17

NOS3 and Myocardial Capillary Development
NOS3 is crucial in the formation of capillaries and angiogenesis.149 To investigate

the role of NOS3 in capillary development, myocardial capillary densities were measured
morphometrically in P1 mouse hearts. Zhao et al. showed that myocardial capillary
densities were decreased in NOS3-/- compared with WT mice.149 Next, in vitro tube
formation of cardiac endothelial cells was investigated on Matrigel. Lack of NOS3
impaired tube formation of endothelial cells. In order to analyze if the decreased tube
formation is related to the level of NO produced by NOS3, NOS3-/- and WT endothelial
cells were treated with an NO donor and a NOS inhibitor, respectively. In vitro tube
formation was inhibited by NG-nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor)
in wild-type cells and restored by a NO donor, diethylenetriamine-NO, in NOS3-/- cells.
In addition, angiogenesis was evaluated via implanting Matrigel in the myocardium of
the adult heart. Following 3 days of implantation, significant angiogenesis is seen in the
implanted Matrigel in WT mice. The angiogenic response was significantly decreased in
the NOS3-/- mice. These data show that deficiency in NOS3 impairs myocardial
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angiogenesis and capillary development, suggesting an important role of NOS3 in
myocardial capillary development.149
1.18

NOS3 and Aortic Valve Development
The morphogenesis of the heart valves occurs concomitantly with changes in the

cardiac morphology and in a complex process that includes initiation, cushion formation,
elongation, valve remodeling and maturation.7, 34 Valve development is initiated during
cardiac looping when the primary myocardium secretes a hyaluronan-rich matrix called
cardiac jelly that projects into the lumen at the atrioventricular junction and the outflow
tract at E9.0 in mice. The underlining myocardial cells produced factors including bone
morphogenetic protein-2 (BMP2), BMP4 and transforming growth factor (TGF)-, which
activate the overlaying endocardium. At E10.5, the activated endocardial cells undergo
EMT to become spindle shaped migratory cells (mesenchymal phenotype) and invade the
cardiac jelly. Proliferation of the mesenchymal cells and matrix deposition extend the
cushions into the cardiac lumen and form primordium of each distinct valve. This is then
followed by elongation and remodeling/thinning of the valve primordial at E12.5, which
leads to the gradual maturation of the valves that are rich in elastin, fibrillar collagen and
proteoglycans. During valve remodeling, cell proliferation decreases, and subsequently
there is little to no proliferation of valve interstitial cells in the adult. Formation of four
distinct valves is a result of septation of the outflow tract into aorta and pulmonary trunk
giving rise to aortic and pulmonary valves, and fusion of the atrioventricular canal
endocardial cushions giving rise to mitral and tricuspid valves.29
Normal aortic valves have 3 distinct cusps (or leaflets) while bicuspid aortic
valves have only 2 cusps.6 Lee et al. were the first to show that deficiency in NOS3
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results in the formation of bicuspid aortic valves. The adult NOS3-/- mice had high
incidences (5/12, 42%) of bicuspid aortic valves.192 Subsequent studies confirmed
bicuspid aortic valves with an incidence of about 30% in NOS3-/- mice.193 In patients with
bicuspid aortic valves, the common subtypes are fusion of right and left coronary leaflets
(R-L) as well as fusion of right and non-coronary leaflets (R-N).6, 194 In NOS3-/- mice, the
bicuspid aortic valve is the R-N subtype in which the left leaflet develops normally.193
Data from the Feng lab also showed that NOS3-/- mice have bicuspid aortic valves.195
Furthermore, these mice have significant aortic regurgitation at postnatal day 1 as
demonstrated by pulsed-wave Doppler and color flow Doppler echocardiography. The
data is consistent with aortic regurgitation seen in patients with bicuspid aortic valves.196
Notch signalling is essential for early embryonic development of aortic valves and
postnatal repression of calcium deposition in the aortic valves. Mutations in the NOTCH1
gene cause autosomal-dominant anomalies of aortic valves and severe valve calcification
in humans.111 In mice, Notch1 transcripts are the most abundant in the developing aortic
valves. Furthermore, Notch1 inhibits the activity of Runx2, a central transcriptional
regulator of osteoblast cell fate. Thus, decreases in Notch1 signaling result in
developmental defect in the aortic valve and postnatal calcification that causes
progressive aortic valve disease.111 Additionally, Notch signalling is also required for the
EMT process in endocardial cushions during early valve development.197 Interestingly,
recent studies have shown that Notch signalling activates NOS3 and its downstream
target, soluble guanylyl cyclase via PI3K/Akt pathway.37 Therefore, NOS3 is likely a
potential downstream target of Notch signalling that governs aortic valve development
and postnatal remodeling.
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1.19

NOS3 and Thrombosis
The role of NO in thrombosis formation has been investigated in animal models

using NOS inhibitors and its substrate L-arginine. Stagliano et al. have shown infusion of
L-NAME, a NOS inhibitor, caused an increase in platelet adhesion in a rat brain stroke
model.198 In a glomerular thrombosis model, administration of endotoxin increased NO
production and this effect was inhibited by infusion of L-NAME. Kidneys from rats
given endotoxin and L-NAME showed enhanced thrombosis in glomeruli as compared
with control with either L-NAME or endotoxin treated alone.199 In a canine model of
coronary occlusion, L-arginine treatment increased lysis of thrombus in the coronary
arteries and inhibited platelet aggregation ex vivo.200 The importance of NOS3 in the
prevention of thrombosis formation has also been demonstrated in the NOS3 knockout
mice.201 These mice showed increased susceptibility to thrombosis, stroke and
atherosclerosis.202-205 Exogenously, treatment with a NO-donor inhibited the upregulation
of platelet surface glycoprotein including selectins and integrins, which are important for
platelet aggregation.206 The molecular basis of the NO effect on platelets has been mainly
attributed to cGMP dependent signalling.207-209 The increased production of cGMP leads
to protein kinase G stimulation which results in fibrinogen binding to calcium-dependent
heterodimeric complex of glycoproteins.207-209 This glycoprotein complex serves as an
activation-dependent receptor for adhesive proteins such as fibrinogen.210 Binding of
fibrinogen to glycoproteins mediated platelet aggregation which is crucial in thrombus
formation. Decreased NO levels are also associated with thrombosis in human
diseases.211, 212 It is well known that thrombosis is a common cause of myocardial
infarction and unstable angina, and platelets from these patients show increased surface
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expression of selectins and active glycoproteins.213, 214 Interestingly, platelets isolated
from these patients produce less NO compared to patients with stable coronary artery
disease.215 The role of human NOS3 polymorphisms in thrombosis has recently been
studied.216-219 It has been shown that NOS3 polymorphism is associated with lower
platelet NO production, higher superoxide release and an increased risk of myocardial
infarction, hypertension, stroke, and stenosis of arteries.216-220 Taken together, these
results suggest that NOS3 variants may influence thrombotic susceptibility in humans.
1.20

NOS3 and Aortic Valve Calcification
Aortic valve calcification can occur spontaneously with increasing age,

atherosclerosis and disease conditions such as diabetes and renal disease.221 It has been
shown that NO inhibits calcification of vascular smooth muscle cells and differentiation
of VSMCs into osteoblastic cells via inhibition of transforming growth factor-β (TGFβ)-induced phosphorylation of Smad2/3 and expression of TGF-β-induced genes such as
plasminogen activator inhibitor-1.222 An inhibitor of cGMP dependent protein kinase
increased osteoblastic differentiation and calcification of vascular smooth muscle cells.
222

In addition, atorvastatin, a statin drug, inhibits calcification and enhances NO

production in the hypercholesterolaemic aortic valves.223 NOS3 protein concentrations
were increased in the atorvastatin treated group. Serum nitrite concentrations were
decreased in the hypercholesterolaemic animals and increased in the group treated with
atorvastatin. 223 These data suggest that NOS3 may act through TGF-β to prevent
calcification of vascular smooth muscle cells and the degree of calcification may relate to
the amount of NO produced. Although the precise role of NOS3 on aortic valve
calcification is not well understood, Bosse et al. have suggested that NOS3 signalling can
27

regulate Notch1, a key molecule in aortic valve calcification and genetically linked to
human calcific aortic valve disease.111 They have shown that calcification of aortic valve
interstitial cells can be prevented or accelerated by gain or loss of NO, respectively. In
addition, overexpression of Notch1 can slow down the progression of valvular
calcification induced by NO inhibition.224 These results suggest that NOS3 do play an
important protective role against aortic valve calcification.
1.21

Summary of Heart Defects in NOS3-/- mice
Cardiac NOS3 expression starts early in cardiogenesis at E9.5 and remains high

until E13.5. This also coincides with the crucial period of rapid heart development and
formation of coronary arteries and aortic valves. Deficiency in NOS3 results in cardiac
hypertrophy, congenital septal defects, and postnatal heart failure.136, 225 In addition,
myocardial capillary densities are decreased in NOS3-/- mice. Furthermore, deficiency in
NOS3 results in high incidence of bicuspid aortic valves. These data suggest that NOS3
plays a critical role in embryonic heart development and morphogenesis of aortic valves
and possibly coronary arteries (Figure 1.1). Although how lack of NOS3 leads to these
cardiac phenotypes is not completely understood, possible mechanisms may include
increases in apoptosis, decreases in cell proliferation, changes in gene expression, and
decreases in EPDC migration and EMT. We anticipate that studies on these mechanisms
of NOS3 during embryonic heart development may lead to therapeutic strategies in the
prevention and treatment of congenital heart disease.
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Figure 1.1. NOS3 is crucial during heart development. NO produced from NOS3 may
promote coronary artery development, proper septal formation, proper valve formation,
capillary development and cardiomyocyte maturation.
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1.22

Rationale and Hypotheses

Overall Hypothesis:
Deficiency of NOS3 results in hypoplastic coronary arteries, atrioventricular valve
insufficiency, and aortic valve calcification and thrombosis.
Overall Objectives (Figure 1.2):
1. Investigate the role of NOS3 in fetal coronary artery development.
2. Investigate the role of NOS3 in fetal atrioventricular valve development.
3. Investigate the role of NOS3 in maintaining normal aortic valve structure and
function in adulthood and aging.

Study 1. Role of NOS3 in coronary artery development
Rationale:
NOS3 is expressed in the embryonic heart at E9.5. Studies have shown that NO
production from NOS3 is critical in cardiogenesis.132 Previous studies have demonstrated
that NOS3 plays an important role in embryonic heart development.136, 180, 181
Furthermore, NOS3 promotes cardiomyocyte proliferation and protects cardiomyocytes
from apoptosis. Deficiency in NOS3 resulted in embryonic and postnatal abnormalities in
heart development.136 NO from NOS3 is an important mediator of vasculogenesis and
angiogenesis. Additionally, studies have shown that development of myocardial
capillaries is impaired in NOS3-/- mice.149 Coronary artery development is a complex
process, which involves the migration of PEO to the looping heart, and subsequent
migration and differentiation of epicardium-derived mesenchymal cells.30, 31 The
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molecular mechanisms regulating coronary artery development are still not well
understood.
Hypothesis:
Deficiency in NOS3 impairs coronary artery development.
Objectives:
1. To analyze coronary artery development in NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/and NOS3Tg mice at E15.5 and P0.
2. To identify the cause of death in the NOS3-/- neonates.
3. To understand the signaling mechanisms by which NOS3 controls coronary artery
development.

Study 2. Role of NOS3 in atrioventricular valve development
Rationale:
NOS3 is important for embryonic heart development. Deficiency in NOS3 leads
to congenital septal defect, bicuspid aortic valves and coronary artery malformation.136,
192, 225

The temporal expression pattern of NOS3 peaks during atrioventricular valve

formation, suggesting that NOS3 may participate in the development of the
atrioventricular valves. However, the role of NOS3 in atrioventricular valve formation
and endothelial to mesenchymal transition is not known.
Hypothesis:
Deficiency in NOS3 impairs atrioventricular valve formation and endothelial to
mesenchymal transition.
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Objectives:
1. To assess atrioventricular valves in NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and
NOS3Tg mice at postnatal day 0.
2. To determine if atrioventricular valve defects in NOS3-/- mice result in functional
deficits.
3. To understand the role of NOS3 in the formation of atrioventricular valves.

Study 3. Lack of NOS3 results in thrombosis, calcification and dysfunction of aortic
valve
Rationale:
The spontaneous formation of a thrombus on the aortic valve is extremely rare in
humans; there are only less than a dozen of case reports in the literature.100-109 However,
aortic valve thrombosis is extremely dangerous, as it could lead to embolization, and
subsequent cerebrovascular events such as stroke, myocardial infarction and death.101-104,
108

These patients are limited to surgery as it is the only available and effective treatment.

The cause of aortic valve thrombosis remains unclear. Mutations in Notch1, an important
factor that is involved in many developmental processes, have been shown to cause aortic
valve disease similar to calcified aortic valve stenosis.111 Additional evidence showed
that NOS3 acts upstream of Notch1 and regulate its expression.224 This would suggest
that disruption in NOS3 signalling would also result in phenotypes similar to that of
Notch1 mutation. Studies have suggested that endothelial damage in bicuspid aortic valve
or calcific aortic valve disease could potential result in the formation aortic valve
thrombosis. 157-160, 164 To our knowledge, spontaneous aortic valve thrombosis has never
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been studied in an animal model. Study 3 investigated the role of NOS3 in normal
maintenance of aortic valve function and its deficiency results in aortic valve thrombosis,
dysfunction and calcification in adulthood and aging.
Hypothesis:
Deficiency in NOS3 leads to aortic valve thrombosis, dysfunction and calcification in
aging mice.
Objectives:
1. To investigate the role of NOS3 in the formation of aortic valve thrombosis in
aging mice.
2. To assess aortic valve function in vivo in NOS3+/+ and NOS3-/- mice at 1, 3, 5, 9
and 12 Months.
3. To analyze the degree of calcification and fibrosis of aortic valve leaflets in
NOS3+/+ and NOS3-/- mice.
4. To understand the role of NOS3 in aortic valve calcification.
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Figure 1.2 Summary of studies 1, 2 and 3 on the role of NOS3 in embryonic heart
development and adult aortic valve function.
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Chapter 2

Nitric oxide synthase-3 deficiency results in hypoplastic coronary arteries and
postnatal myocardial infarction

A version of this chapter has been published in European Heart Journal 2014, 35(14):
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“Nitric oxide synthase-3 deficiency results in hypoplastic coronary arteries and postnatal
myocardial infarction.”
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2.1

CHAPTER SUMMARY

Aims: Hypoplastic coronary artery disease is a rare congenital abnormality that is
associated with sudden cardiac death. However, molecular mechanisms responsible for
this disease are not clear. The aim of the present study was to assess the role of nitric
oxide synthase-3 (NOS3) in the pathogenesis of hypoplastic coronary arteries.
Methods and Results: Wild-type (WT), NOS3-/- and a novel cardiac specific NOS3
overexpression mouse model were employed. Deficiency in NOS3 resulted in coronary
artery hypoplasia in fetal mice and spontaneous myocardial infarction in postnatal hearts.
Coronary artery diameters, vessel density and volume were significantly decreased in
NOS3-/- mice at postnatal day 0. In addition, NOS3-/- mice showed a significant increase
in ventricular wall thickness, myocardial volume and cardiomyocyte cell size compared
with WT mice. Lack of NOS3 also down-regulated the expression of Gata4, Wilms
tumor-1, vascular endothelial growth factor, basic fibroblast growth factor and
erythropoietin, and inhibited migration of epicardial cells. These abnormalities and
hypoplastic coronary arteries in the NOS3-/- mice were completely rescued by the cardiacspecific overexpression of NOS3.
Conclusion: NOS3 is required for coronary artery development and deficiency in NOS3
leads to hypoplastic coronary arteries.
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2.2

INTRODUCTION
Congenital coronary anomalies affect up to 5% of the general population.1, 2 Most of

these do not have clinical signs or symptoms, and are often unrecognized. However, severe
congenital coronary artery malformation is associated with myocardial ischemia, infarction
and sudden cardiac death.3 Hypoplastic coronary artery disease (HCAD), a rare congenital
coronary abnormality, is defined by malformation of one or more major branches of the
coronary arteries with a marked decrease in luminal diameter and length.4-6 HCAD can be
asymptomatic, but is often associated with myocardial infarction and sudden cardiac death
under stress, such as during intense physical activity.3, 7 However, the molecular
mechanisms responsible for embryonic development of HCAD are still unknown.
Nitric oxide (NO) is produced from the guanidino group of L-arginine in an
NADPH-dependent reaction catalyzed by a family of NO synthase (NOS) enzymes.8
Originally identified as a vasodilatory agent, NO is now recognized as an important
signaling molecule involved in a wide range of physiological processes including
apoptosis, angiogenesis and cell growth.8, 9 There are 3 distinct isoforms of NOS:
neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2) and endothelial NOS
(eNOS, NOS3). Interestingly, NOS3 is expressed in cardiomyocytes during early
mammalian embryonic heart development.10 Immunohistochemical analysis revealed that
the heart starts to express NOS3 at E9.5 and the expression remains high until E13.5.
Starting from E14.5 the levels of NOS3 expression decreases in both atria and
ventricles.10 The expression of NOS3 in the heart peaks during coronary artery
development,10, 11 suggesting its potential importance. However, the role of NOS3 in
embryonic coronary artery development is still not clear.
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The signaling milieau within the developing heart is critical to coronary
vasculogenesis.11 Transcription factors such as Gata4 and Wilms tumor-1 (Wt1),12, 13 as
well as growth factors including vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (FGF) and erythropoietin (EPO) 14, 15 are essential in the
formation of coronary arteries.11, 15 We have previously shown a key role of NOS3 to
capillary vessel development in the heart.16 In the present study, we hypothesized that
NO production from NOS3 within the embryonic heart is a critical signaling molecule in
the development of coronary arteries and deficiency in NOS3 results in hypoplastic
coronary arteries.
2.3

METHODS

2.3.1 Animals
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (NOS3+/+)
mice were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program
was carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was
performed by a polymerase chain reaction (PCR) method using genomic DNA prepared
from tail biopsies. A timed breeding program was carried out. Vaginal plug was
monitored in the morning of each day and a plug was considered 0.5 days into pregnancy.
Embryonic hearts were collected at E12.5, E15.5 and postnatal day 0 (P0). All procedures
involving mouse husbandry and manipulation were in accordance with the guidelines of
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at
the University of Western Ontario, Canada.
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2.3.2 Generation of Human NOS3 Transgenic Mice
A new line of cardiac-specific mice overexpressing human isoforms of NOS3
(NOS3Tg) was generated. Briefly, human NOS3 complementary DNA was inserted into
the β-myosin heavy chain promoter expression vector to permit the expression of human
NOS3 only during embryonic development and specifically in the heart. Genotypes were
identified by PCR using genomic DNA from tail biopsies. Primer sequence is shown in
Table 1. Relative protein expression of varies genotypes were done via western blotting
and immunohistochemical staining.
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Table 2.1 Gene name, accession number and primers used.
Gene

Accession #

Primer Sequence

Hu-NOS3

NM_000603.3

Sense: 5’ CTC GTG TGA AGA ACT GGG AGG T 3’
Antisense: 5’ GTG GCA TAC TTG ATG TGG TTG 3’

28S

NR_003279.1

Sense: 5’ TTG AAA ATC CGG GGG AGA G 3’
Antisense: 5’ ACA TTG TTC CAA CAT GCC AG 3’

Gata4

NM_008092.3

Sense: 5’ CAC TAT GGG CAC AGC AGC TC 3’
Antisense: 5’ GCC TGC GAT GTC TGA GTG AC 3’

VEGFa

NM_001025250.2

Sense: 5’ GAT TGA GAC CCT GGT GGA CAT C 3’
Antisense: 5’ TCT CCT ATG TGC TGG CTT TGG T 3’

FGF

NM_008006.1

Sense: 5’ CAA GGG AGT GTG TGC CAA CC 3’
Antisense: 5’ TGC CCA GTT CGT TTC AGT GC 3’

EPO

NM_007942.2

Sense 5’ GGA ATT GAT GTC GCC TCC AG 3’
Antisense: 5’ GCA GCA GCA TGT CAC CTG TC 3’

Wt1

NM_144783.2

Sense: 5’ GAT GTG CGG CGT GTA TCT GG 3’
Antisense: 5’ GCT GGT CTG AGC GAG AAA ACC T 3’

2.3.3 ECG Monitoring
Short-term monitoring of ECG limb lead was performed in anesthetized mice
with needle electrodes inserted subcutaneously. ECG was recorded with Powerlab Chart
5.0 (AD Instruments, Colorado Springs, CO).
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2.3.4 TTC Staining
Neonatal hearts were first dissected out of the body, cut in half and washed in
PBS to remove blood. Next, they were incubated in 1% TTC solution at room
temperature for 1 hour. Finally, images are taken on a microscope for macro samples
(Discovery V8., Zeiss, Germany).
2.3.5 Three-Dimensional Reconstructions and Histological Analysis
Three-dimensional (3D) reconstructions of the heart and coronary arteries were
performed using α-smooth muscle actin stained serially sections of P0 and E15.5 hearts
through the AMIRA® software (Template Graphics Software, USA). Briefly, stained
serially sections were imaged (Observer D1, Zeiss, Germany). These images were then
used for 3D reconstructions of the heart and measurements of coronary artery diameter,
abundance and myocardial wall thickness. All measurements were made at similar
anatomical location to ensure consistency. Calculations of myocardial and coronary
artery volume were made using the AMIRA® program.
2.3.6 Ex vivo Heart Cultures
E12.5 NOS3+/+ and NOS3-/- hearts were explanted and cultured in M199 medium
(Sigma-Aldrich, USA). Hearts were stabilized for 2 hours prior to any treatment. Both
NOS3+/+ and NOS3-/- hearts were beating throughout the entirety of the experiment.
NOS3+/+ and NOS3-/- hearts were treated with 100 µM ODQ (Sigma-Aldrich Chemie,
USA) and 2 mM 8-Bromo-cGMP (Sigma-Aldrich Chemie, USA), respectively for 6
hours. Hearts were then collected and mRNA levels of Wt1 and Gata4 were analyzed by
real time RT-PCR.
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2.3.7 Co-culture of EPDCs and Cardiomyocytes
E13 eGFP+ hearts were planted on a 35 mm petri dish for 3 days to allow
outgrowth of epicardial cells, which are epicardial-derived cells (EPDCs). After 3 days,
the hearts were removed and eGFP+ EPDCs were cultured for 3 more days prior to coculture with NOS3+/+ or NOS3-/- cardiomyocytes. NOS3+/+ and NOS3-/- cardiomyocytes
were isolated according to previous protocol with the following modifications. E13
NOS3+/+ and NOS3-/- embryos were collected and hearts were carefully dissected out of
the embryo. The co-culture system functions similar to a wound healing assay system
(Fig. 2.8A). Cardiomyocytes isolated from E13 NOS3+/+ and NOS3-/- mice were plated on
the inside of the barrier overnight with or without the treatment of adenoviral NOS3 or
lacZ. eGFP+ EPDCs were cultured on the outside of the barrier for 2 hours before the
barrier was removed. After the barrier was removed, the eGFP+ cells were given 72 hours
to migrate. Images were then taken under a confocal microscope (LSM 510 Meta, Zeiss,
Germany). In order to obtain a complete view, a tiled scan was performed to piece
together 16 images at 40x into a unified image.
2.3.8 General Tissue Processing
Neonatal NOS3+/+, NOS3+/-, NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg mice were used
for analysis. Neonatal hearts and lungs were isolated and fixed in 4% paraformaldehyde,
dehydrated, and embedded in paraffin. Five micro-meter transverse serial sections were
mounted onto albumin/glycerin coated glass slides.
2.3.9 Real Time RT-PCR
Total RNA was isolated from cultured fetal hearts with a RNA isolation kit
(Qiagen, Canada). cDNA was synthesized using M-MLV (Invitrogen, Canada) reverse
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transcriptase and random primers (Invitrogen, Canada). Real-time PCR was conducted
using SYBR Green PCR Master Mix as per manufacturer's instructions (Eurogentec,
USA). The oligonucleotide primers used in this study are summarized in Supplementary
Table 1. Samples were amplified for 35 cycles using MJ Research Opticon Real-Time
PCR machine. The expression levels of Gata4, VEGFa, FGF, EPO, and Wt1 in relation
to 28S rRNA as a loading control were obtained.
2.3.10 Immunohistochemistry and Immunofluorescence
After deparaffination and rehydration of the slides, microwave antigen retrieval
was applied by heating them for 10 min at 98°C in a citric acid buffer (0.01 M in aquadest, pH 6.0). Inhibition of endogenous peroxidase was performed with a solution of 0.3%
H2O2 in phosphate buffered saline (PBS) for 30 min. The slides were incubated overnight
with either 1:500 anti-troponin I (Santa Cruz Biotechnology, USA), 1:3,000 anti-αsmooth muscle actin (Sigma- Aldrich, USA), 1:500, 1:300 anti-Wt1 (Calbiochem, USA)
or 1:1000 anti-NOS3 (BD Transduction Laboratories, USA). Next, the secondary
antibodies was added for 60 min with either 1:200 horse anti-mouse biotin (Vector
Laboratories, USA) or 1:200 goat anti-rabbit biotin (Vector Laboratories, USA) in PBS.
Subsequently, slides were incubated with ABC reagent (Vector Laboratories, USA) for
30 min. For visualization, the slides were incubated with 400 μg/ml 3-3’diaminobenzidin tetrahydrochloride (Sigma-Aldrich Chemie, USA) and 100 μL of 30%
H2O2 dissolved in PBS for 10-15 min. Counterstaining was performed with 0.1%
hematoxylin (Merck, Germany). For immunofluorescence staining, following primary
antibody incubation, 1:500 goat anti-rabbit fluorescent secondary antibody (Jackson
ImmunoResearch, USA) was used. Nuclei were stained with 1:50000 Hoechst 33342
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(Invitrogen, Canada). Cardiomyocyte membranes were stained with 1:300 WGA (Vector
Laboratories, USA).
2.3.11 Western Blot Analysis
Forty micrograms of protein lysates were subjected to separation on a 12% SDSPAGE gel, followed by electrotransfer to nitrocellulose membranes. Blots were probed
with specific antibodies against NOS3 (BD Biosciences, USA) and GAPDH (Santa Cruz
Biotechnology, USA), respectively. Signals were detected by the chemiluminescence
detection method.
2.3.12 Heart Function Measurements
Left ventricular (LV) ejection fraction and fractional shortening were measured
using Vevo 2100 (Visual Sonics, Canada). Briefly, 2-dimensional images of the heart
were obtained in short-axis view using a dynamically focused 40 MHz probe. The Mmode cursor was positioned perpendicular to the LV anterior and posterior walls. The LV
internal end-diastolic dimension (LVIDd) and LV internal systolic dimension (LVIDs)
were measured from M-mode recordings. LV ejection fraction was calculated as: EF (%)
= [(LVIDd)3 - (LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%)
= (LVIDd-LVIDs)/LVIDd×100. The M-mode measurements of the left ventricular
ejection fraction and fractional shortening were averaged from 3 cycles.
2.3.13 EPDC Outgrowth
E12.5 NOS3+/+ and NOS3-/- hearts were planted on a 35 mm petri dish for 3 days
to allow outgrowth of epicardial cells, which are epicardial-derived cells (EPDCs). After
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3 days, these hearts were imaged under phase contrast (Observer D1, Zeiss, Germany).
Their maximum migration distance was measured.
2.3.14 Statistical Analysis
Data are presented as mean±SEM. Survival curves were created by the method of
Kaplan and Meier and compared by log-rank test. Unpaired Student’s t test was used for
2 group comparisons. One way ANOVA followed by Student-Newman-Keuls test was
performed for multi-group comparisons. Two way ANOVA test was performed for multigroup, multi-treatment comparisons. A two-sided P<0.05 was considered statistically
significant. All statistical analyses were performed using GraphPad Prism software 3.0.

2.4

RESULTS

2.4.1 Characterization of NOS3TG and NOS3TG;NOS3-/- mice.
In order to study the specific role of NOS3 in coronary artery development, a
cardiac-specific NOS3 transgenic mouse (NOS3Tg) was generated under the control of myosin heavy chain promoter.17 Expression of human NOS3 was detected only during
embryonic development and specifically in the heart of NOS3Tg mice (Figure 2.1A-D).
The NOS3Tg mice were then crossed with NOS3-/- to create the NOS3Tg;NOS3-/- mouse, an
animal that lacks NOS3 in all organs except the heart during embryogenesis (Figure 2.1B,
D). Since the gaseous molecule NO can freely diffuse between cells, NOS3
overexpression in cardiomyocytes rescued NOS3 expression in NOS3-/- hearts.
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Figure 2.1 Generation of mice with cardiomyocyte specific overexpression of human
nitric oxide synthase-3 (hu-NOS3) during embryonic development. (A) Construct used
for the generation of mice with cardiomyocyte specific overexpression of hu-NOS3 under
the control of -myosin heavy chain (MHC). (B) NOS3 protein levels in the heart at
E12.5, P0 and 5 months of age by Western blot analysis. Tg;-/- and Tg;+/+ indicate
NOS3Tg;NOS3-/- and NOS3Tg, respectively. (C) Expression of the hu-NOS3 transgene was
restricted in the heart at P0. Hu-NOS3 mRNA was analyzed by RT-PCR. (D) Western
blot analysis showed decreased NOS3 expression from NOS3+/+ to NOS3+/- to NOS3-/animals. (E) NOS3 immunostaining at E12.5 showing expression of the Hu-NOS3
transgene. Endogenous NOS3 expression was mostly located in the endocardium and
capillary endothelium in the NOS3+/+ mice. NOS3-/- mice showed no detectable
expression of NOS3. NOS3Tg;NOS3-/- mice showed strong NOS3 expression in the
myocardium, but not in the endocardium or capillary endothelium. NOS3Tg mice showed
strong NOS3 expression in the myocardium (transgene), endocardium and capillary
endothelium (endogenous). Scale bar = 30 μm.
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2.4.2 Deficiency in NOS3 results in spontaneous myocardial infarction.
Deficiency in NOS3 resulted in 73% mortality within the first 4 days after birth
(Figure 2.2E). Coronary artery malformation may lead to myocardial ischemia and cell
death, resulting in myocardial infarction. To assess if myocardial infarction was the cause
of death, P0 hearts were subjected to triphenyltetrazolium chloride (TTC), troponin I and
hematoxylin/eosin (H/E) staining. TTC staining showed that NOS3-/- mice had a large
area of tissue death near the apex of the heart (Figure 2.2A). Troponin I is a part of the
troponin complex that is integral to muscle contraction and decreased levels of troponin I
represent cardiomyocyte death.18 Our data showed troponin I immunostaining was
decreased in the area of infarct in NOS3-/- mice (Figure 2.2A). H/E staining showed
typical wavy fibers near the border of the infarct area with disappearance of nuclei and
intense eosinophilic cytoplasm (Figure 2.2A), which are signs of acute myocardial
infarction.19 ECG monitoring showed ST elevation and QRS inversion in neonatal NOS3/-

mice, indicating myocardial ischemia and possible cardiac hypertrophy, respectively

(Figure 2.2A). Spontaneous myocardial infarction was seen in 8/15 (53%) NOS3-/animals at P0 (Figure 2.2B). Consequently, left ventricular ejection fraction and
fractional shortening were significantly decreased in the NOS3-/- compared to NOS3+/+
mice (P<0.05, Figure 2.2C-D). These abnormalities in NOS3-/- mice including myocardial
infarction, cardiac dysfunction, and postnatal mortality were all rescued by cardiacspecific overexpression of NOS3 (NOS3Tg;NOS3-/- mice, Figure 2.2A-E).
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Figure 2.2 Myocardial infarction and postnatal survival in NOS3-/- mice. (A) Evidence of
spontaneous myocardial infarction in NOS3-/- mice at P0. TTC staining shows a large
area of tissue death near the apex of the heart. The images are adjacent cross sections of
the heart near the apex. Troponin I staining shows a significant loss of troponin I in the
infarct myocardium. H/E staining shows waviness of fibers near the border of the
myocardium with intense eosinophilic cytoplasm. ECG tracing shows significant ST
elevation (Arrows) and QRS inversion (Arrowheads), representing signs of myocardial
ischemia and possible cardiac hypertrophy, respectively. White bar: 1mm. Black bar:
40µm. (B) Spontaneous myocardial infarction in NOS3-/- animals at P0. * P<0.01 vs.
NOS3+/+, NOS3Tg;NOS3-/- and NOS3Tg mice. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/and NOS3Tg, respectively. (C-D) Heart function assessed by echocardiography in
NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and NOS3Tg mice at P0. N=5-6 mice per group. *
P<0.01 vs. NOS3+/+ mice. † P <0.01 vs. NOS3-/-. (E) Thirty-day survival after birth in
NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and NOS3Tg mice. * P<0.001 vs. NOS3+/+,
NOS3Tg;NOS3-/- and NOS3Tg mice.
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2.4.3 Deficiency in NOS3 impairs coronary artery development.
NOS3-/- and NOS3+/- hearts at P0 showed less branching and significant decreases
in the left and right coronary artery diameters (Figure 2.3A-D). Three-dimensional
reconstructions of the heart showed a significant decrease in coronary volume in NOS3-/mice (P<0.01, Figure 2.3E, Figure 2.4A ). Cardiomyocyte-specific NOS3 overexpression
completely rescued these defects in the NOS3-/- mice (Figure 2.3A-E, Figure 2.4A).
Since a decrease in coronary artery volume may have been a result of a smaller
myocardial mass, myocardial volume and thickness were analyzed. However, both
myocardial volume and thickness were increased in NOS3-/- and NOS3+/- compared to
NOS3+/+ mice (P<0.01, Figure 2.4B-C). In order to determine if the increased myocardial
volume and thickness are a result of cardiac hypertrophy, cardiomyocyte cell size and
nuclear size of P0 hearts were measured. Cardiomyocyte cell and nuclear size was
progressively increased in NOS3-/- and NOS3+/- compared to NOS3+/+ mice (P<0.01,
Figure 2.4D-E). Therefore, our data showed an increased myocardial mass accompanied
by severe coronary artery hypoplasia. These defects NOS3-/- mice were completely
rescued by cardiomyocyte-specific NOS3 overexpression (P<0.01, Figure 2.4B-E).
The coronary artery network is established by E15.5 in mice.11 To assess the onset
of the coronary artery malformations, we further analyzed coronary artery development at
E15.5. Coronary artery abundance, vessel diameter and volume were all significantly
decreased while myocardial thickness was increased in NOS3-/- compared to NOS3+/- and
NOS3+/+ mice at E15.5 (P<0.01, Figure 2.5A-F). These results suggest that the onset of
the defect is prior to E15.5. Consistent with our P0 data, these defects were completely
rescued by cardiomyocyte-specific NOS3 overexpression (P<0.01, Figure 2.5A-F). Since
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coronary artery formation at E15.5 was not impaired in NOS3+/- mice, all subsequent
molecular analyses on early coronary artery development were carried out in NOS3-/- in
comparison with NOS3+/+ mice.
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Figure 2.3 Immunohistochemical analysis of coronary artery development at P0. (A)
Heart sections were stained with vascular smooth muscle α-actin to identify coronary
arteries. Coronary arteries were smaller and less abundant in NOS3-/- and NOS3+/compared to NOS3+/+ mice. Cardiac specific overexpression of NOS3 (NOS3Tg;NOS3-/-)
restored coronary abundance in NOS3-/- mice. Coronary arteries are indicated by red
arrows. Scale bar = 60 μm. (B-D) Left and right coronary artery diameter and abundance
measured at 50 µm from the aortic orifice were significantly decreased NOS3-/- and
NOS3+/- compared to NOS3+/+ mice, which was restored in NOS3Tg;NOS3-/- mice. N=5
hearts per group.* P<0.01 vs. NOS3+/+, † P <0.01 vs. NOS3+/-. ‡ P <0.01 vs. NOS3-/-.
Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg, respectively. (E) Coronary
artery volume was significantly decreased NOS3-/- and NOS3+/- compared to NOS3+/+
mice, which was restored in NOS3Tg;NOS3-/- mice. N=5 hearts per group. * P<0.01 vs.
NOS3+/+. † P <0.01 vs. NOS3-/-.
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Figure 2.4 3D reconstruction of coronary artery development at P0. (A) Coronary
arteries shown in green were less abundant in NOS3-/- and NOS3+/- compared to NOS3+/+
mice. Cardiac specific overexpression of NOS3 restored coronary artery abundance in
NOS3-/- mice. Atria were excluded from the reconstruction in order to view the origins of
the coronary arteries. (B-C) Ventricular wall thickness and myocardial volume were
significantly increased in NOS3-/- and NOS3+/- compared to NOS3+/+ mice. Cardiac
overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial thickness and volume to
similar levels as in the NOS3+/+ mice. (D-E) Cross-section cardiomyocyte cell and
nucleus size was significantly increased NOS3-/- and NOS3+/- compared to NOS3+/+ mice.
Cardiac overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial thickness to
similar levels as in the NOS3+/+ mice. N=4 hearts per group. *P<0.01 vs. NOS3+/+mice,
†P<0.01 vs. NOS3+/- mice, ‡P <0.01 vs. NOS3-/-. Tg;-/- and Tg;+/+ indicate
NOS3Tg;NOS3-/- and NOS3Tg, respectively.
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Figure 2.5 Coronary artery development at E15.5. (A) 3D reconstruction of E15.5 hearts.
Coronary arteries shown in green were less abundant in NOS3-/- compared to NOS3+/- and
NOS3+/+ mice. Cardiac specific overexpression of NOS3 restored coronary artery
abundance in NOS3-/- mice. Atria were excluded from the reconstruction in order to view
the origins of the coronary arteries. (B-E) Coronary artery vessel diameter, abundance
and volume were significantly decreased in NOS3-/- mice compared to NOS3+/- and
NOS3+/+, which were restored in NOS3Tg;NOS3-/- mice. N=5 hearts per group. Tg;-/- and
Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg, respectively. (F) Ventricular wall thickness
was significantly increased in NOS3-/- compared to NOS3+/- and NOS3+/+ mice.
Cardiomyocyte specific overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial
thickness to similar levels as in the NOS3+/+ mice. N=4 hearts per group. For B-F,
*P<0.01 vs. NOS3+/+ mice, † P<0.01 vs. NOS3-/-.
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2.4.4 Down-regulation of transcription and growth factors in E12.5 NOS3-/- hearts.
Capillary networks in the embryonic heart begin to develop at E12.5, and are
regulated by transcription and growth factors that are critical to heart morphogenesis and
coronary artery formation.11 Our data showed that the mRNA levels of Gata4, VEGFa,
FGF and EPO were significantly decreased in the NOS3-/- compared with NOS3+/+ hearts,
and were completely restored in the NOS3Tg;NOS3-/- hearts (P<0.05, Figure 2.6A-D).
Treatment with ODQ, a soluble guanylyl cyclase inhibitor significantly decreased Gata4
and Wt1 mRNA expression in the NOS3+/+ hearts (P<0.05, Figure 2.6E-F). Conversely,
NOS3-/- hearts treated with 8-Bromo-cGMP, a cGMP analog showed a significant
increase in Gata4 and Wt1 mRNA levels (P<0.05, Figure 2.6G-H). These data suggest
that NOS3 regulates the expression of Gata4 and Wt1 through a cGMP-dependent
signaling pathway.
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Figure 2.6 Myocardial mRNA expression of transcription and growth factors. (A-D)
E12.5 hearts were collected and mRNA levels of Gata4, VEGFa, FGF and EPO were
analyzed by real-time RT-PCR. The mRNA levels of Gata4, VEGFa, FGF and EPO were
significantly decreased in NOS3-/- compared with NOS3+/+ mice, which were restored by
cardiac specific NOS3 overexpression in the NOS3Tg;NOS3-/- hearts. N=6-7 per group. *
P<0.01 vs. NOS3+/+ mice. † P <0.01 vs. NOS3-/- mice. Tg;-/- and Tg;+/+ indicate
NOS3Tg;NOS3-/- and NOS3Tg, respectively.
(E-H) E12.5 ex vivo heart cultures were used to investigate NOS3 signaling. Cultured
NOS3+/+ and NOS3-/- hearts were treated with 100 µM ODQ, a soluble guanylate cyclase
inhibitor, or 2 mM 8-Br-cGMP, a cGMP analog, for 6 hrs. ODQ decreased Gata4 and
Wt1 mRNA levels in NOS3+/+ hearts while 8-Br-cGMP restored Gata4 and Wt1 mRNA
levels in NOS3-/- hearts. N=3-4 heart cultures per group. * P<0.05 vs. controls.
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2.4.5 Deficiency in NOS3 decreases epicardium-derived cells (EPDCs) migration.
EPDCs express Wt1 and their migration into the myocardium is essential to the
formation of coronary arteries.13, 20 The number of Wt1+ epicardial cells was significantly
decreased in NOS3-/- compared to NOS3+/+ hearts at E12.5 (P<0.01, Figure 2.7A-B). In
addition, myocardial Wt1 mRNA levels were also significantly decreased in NOS3-/compared with NOS3+/+ mice (P<0.01, Figure 2.7C). Decreased myocardial expression of
Wt1 and number of Wt1+ epicardial cells were rescued in NOS3Tg;NOS3-/- mice (P<0.01,
Figure 2.7A-C). To study the role of NOS3 in EPDCs migration, a co-culture system was
employed (Figure 2.8A). EPDCs were isolated from E13 embryos overexpressing
enhanced green fluorescence protein (eGFP). The cultured EPDCs were typical cobble
stone shape and 100% positive for epicardin and Wt1. Cardiomyocytes was verified by αactinin staining (Figure 2.8B). eGFP+ EPDCs were then co-cultured with either E13
NOS3+/+ or NOS3-/- cardiomyocytes treated with adenoviral lacZ or adenoviral NOS3 for
72 hours. Our data showed migration of eGFP+ EPDCs was significantly decreased
towards the NOS3-/- compared to the NOS3+/+ cardiomyocytes (Figure 2.8C-D). However,
EPDC migration was increased in cardiomyocytes treated with adenoviral NOS3
compared to adenoviral lacZ controls (Figure 2.8C-D). Finally, to assess EPDC migration
and proliferation in the developing heart, ex vivo heart explants were employed. Our data
showed ex vivo EPDC migration and proliferation were significantly decreased in the
NOS3-/- compared with NOS3+/+ hearts (P<0.01, Figure 2.8E-F).
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Figure 2.7 Characterization and quantification of Wt1+ epicardial progenitor cells. (A)
E12.5 hearts were immunostained for Wt1 and representative images from NOS3+/+,
NOS3-/- , NOS3Tg;NOS3-/- and NOS3Tg hearts are shown. The majority of Wt1+ cells are in
the epicardium with limited expression in the myocardium. Scale bar = 60 μm. (B)
Quantitative analysis showed a significant reduction in Wt1+ epicardial cells in NOS3-/compared with NOS3+/+ hearts, which was restored by cardiac specific NOS3
overexpression in the NOS3Tg;NOS3-/- hearts. N=4-5.
(C) Wt1 mRNA levels were analyzed in E12.5 hearts by real time RT-PCR. Wt1 mRNA
expression was significantly decreased in the NOS3-/- compared with NOS3+/+ hearts,
which was restored in NOS3Tg;NOS3-/- hearts. N=6-7 per group. For B and C, *P<0.01 vs.
NOS3+/+ mice, † P<0.01 vs. NOS3-/-. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and
NOS3Tg, respectively.
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Figure 2.8 Migration of epicardium-derived cells (EPDCs). (A) EPDCs were isolated
from E13 hearts and co-cultured with cardiomyocytes as shown. The number of EPDCs
migrated towards the cardiomyocytes was determined. (B) A representative confocal tiled
image of the EPDCs and cardiomyocyte co-culture. EPDCs (green) and cardiomyocytes
were isolated from eGFP transgenic and C57BL6 wild-type mice, respectively.
Cardiomyocytes were stained with cardiac -actinin (red). (C) Quantitative analysis from
(D) shows that EPDC migration was significantly decreased in NOS3-/- compared to
NOS3+/+ cardiomyocyte co-cultures, which was restored by adenoviral NOS3 treatment.
N=3-5 per group. *P<0.01 vs. NOS3+/+ mice. †P<0.01 vs. respective Ad-lacZ treated
groups. (D) NOS3 expression in cardiomyocytes promoted EPDCs migration.
Representative confocal tiled images of eGFP+ EPDCs co-cultured with NOS3+/+ and
NOS3-/- cardiomyocytes, which were treated lacZ or NOS3 adenoviral constructs.
(E) Representative images of EPDC outgrowth of E12.5 NOS3+/+ and NOS3-/- hearts.
Scale bar = 250 μm. (F) Quantitative analysis shows that maximum EPDC migration
distance was significantly decreased in NOS3-/- hearts compared with NOS3+/+ hearts.
N=7-8, *P<0.01 vs. NOS3+/+ heart. (G) Proposed signaling pathway of NOS3 on
coronary artery development. NOS3 promotes the expression of Gata4 and Wt1 via
cGMP-dependent mechanisms. The production of growth factors (VEGFa, FGF and EPO)
by Gata4 and EPDCs migration by Wt1 contribute to the critical role of NOS3 on
coronary artery development. Dash lines represent signalling pathways shown by others.
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2.5

DISCUSSION
Growing evidence suggests that NO plays an important role in embryonic heart

development. To this end, we and others have previously shown that lack of NOS3
results in congenital septal defects and bicuspid aortic valves in mice.21-24 In addition,
impaired capillary and microvessel development has been shown in the heart and lungs of
NOS3-/- mice, respectively.16, 25 The present study was carried out to further examine the
role of NOS3 in coronary artery development. We demonstrated for the first time that
deficiency of NOS3 leads to hypoplastic coronary arteries. These results show that NOS3
plays a critical role in normal coronary artery development (Figure 2.8G). To rescue the
coronary phenotype in the NOS3-/- mice, we generated a mouse with cardiomyocytespecific overexpression of NOS3 during embryonic development. The NOS3Tg mice had
a normal cardiac and coronary artery phenotype. Importantly, cardiomyocyte-specific
overexpression of NOS3 completely rescued the abnormal coronary artery development,
cardiac hypertrophy and postnatal survival in the NOS3-/- mice. The data strongly suggest
that normal coronary artery development is driven by local NO signaling from
endothelial cells and/or cardiomyocytes within the developing heart.
Our data showed that deficiency in NOS3 down-regulated the expression of Gata4,
VEGFa, FGF and EPO in the embryonic heart. Additionally, Wt1, a transcription factor
critical for EMT and coronary artery formation, was also down-regulated and the number
of EPDCs was decreased in the NOS3-/- hearts. Furthermore, lack of NOS3 decreased
EPDCs migration towards the cardiomyocytes. Flow dependent dilation and remodeling
are important mechanisms in the regeneration of adult blood vessels.11, 15 However,
initiation of embryonic coronary artery development relies more on de novo arterial
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plexuses formation that are independent of blood flow. Eventually at around E14.5,
arterial plexuses are connected and the connection of coronary artery to the aorta is made.
After this point, flow dependent dilation and remodeling in the coronary artery are
important in establishing further expansion of the vessels similar to adult blood vessel
generation.11, 15 This process, however, is not NOS3 dependent.26 Our results show that
NOS3 promotes normal coronary artery development via increases in expression of
transcription and growth factors, and EPDCs migration into the myocardium (see Figure
2.8G).
NOS3-/- mice have a high rate of postnatal mortality. We have previously shown
that within 10 days after birth, mortality was 85%, 38% and 13% for NOS3-/-, NOS3+/and WT mice, respectively.21 Most animals died within the first 3 days after birth.
Consistent with our finding, Han et al. showed that 40% of NOS3-/- offspring succumbed
within the first hour of birth.25 However, they did not monitor their animal survival
beyond one hour of birth. In the present study, the mortality of NOS3-/- mice was 73% in
the first 4 days after birth, which is in agreement with the previous studies.21, 25
Additionally, we demonstrated a dose-dependent cardiac dysfunction at P1 with the loss
of one or both NOS3 alleles.21 Interestingly, this gene dose-dependent response was also
observed in the coronary artery formation of NOS3-/-, NOS3+/- and NOS3+/+ mice at P0 in
the present study. These data suggest that hypoplastic coronary arteries may contribute at
least in part to postnatal cardiac dysfunction and mortality in NOS3-/- mice.
Hypoplastic coronary artery disease (HCAD) is often associated with myocardial
infarction and sudden cardiac death when the heart is stressed.7 In the present study,
coronary artery malformation is accompanied by spontaneous myocardial infarction in
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postnatal NOS3-/- mice. Our study demonstrated that NOS3 deficiency results in
hypoplastic coronary arteries, a condition that mirrors HCAD in humans. Interestingly,
recent studies have shown that a common 894G>T single nucleotide polymorphism,
which reduces NOS3 activity, is associated with up to 2.3 fold increased risk of
congenital heart disease, especially conotruncal heart defects.27 In addition,
environmental factors and maternal conditions including psychological stress,
hypertension and diabetes, which decrease NOS3 expression and/or activity, are
associated with increased risks of congenital heart disease.28-30 Thus, it is possible that
decreased NOS3 signaling may promote the development of congenital heart disease in
patients with these environmental and maternal conditions. Although further studies are
required to analyze NOS3 gene mutation in patients with HCAD, the present study
suggests NOS3 is critical to coronary artery development and deficiency or mutation of
NOS3 gene may lead to HCAD. Our study is the first to implicate NOS3 deficiency in
the pathogenesis of HCAD and may help to design strategies in the diagnosis, prevention
and treatment of HCAD in humans.
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CHAPTER 3

Nitric Oxide Synthase-3 Promotes Embryonic Development of Atrioventricular
Valves
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3.1

CHAPTER SUMMARY

Aims: Nitric oxide synthase-3 (NOS3) has recently been shown to promote endothelialto-mesenchymal transition (EndMT) in the developing atrioventricular (AV) canal. The
present study was aimed to investigate the role of NOS3 in embryonic development of
AV valves. We hypothesized that NOS3 promotes embryonic development of AV valves
via EndMT.
Methods and Results: To test this hypothesis, morphological and functional analysis of
AV valves were performed in wild-type (WT) and NOS3-/- mice at postnatal day 0. Our
data show that the overall size and length of mitral and tricuspid valves were decreased in
NOS3-/- compared with WT mice. Echocardiographic assessment showed significant
regurgitation of mitral and tricuspid valves during systole in NOS3-/- mice. These
phenotypes were all rescued by cardiac specific NOS3 overexpression. To assess EndMT,
immunostaining of Snail1 was performed in the embryonic heart. Snail1 positive and
total mesenchymal cells in the AV cushion were decreased in NOS3-/- compared with WT
mice at E10.5 and E12.5, which was completely restored by cardiac specific NOS3
overexpression. In cultured embryonic hearts, NOS3 promoted transforming growth
factor (TGFβ), bone morphogenetic protein (BMP2) and Snail1expression through cGMP.
Furthermore, mesenchymal cell formation and migration from cultured AV cushion
explants were decreased in the NOS3-/- compared with WT mice.
Conclusion: NOS3 promotes AV valve formation during embryonic heart development
and deficiency in NOS3 results in AV valve insufficiency.
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3.2

INTRODUCTION
Valvular heart disease is a significant health problem and contributes to more than

44,000 deaths in United States annually.1 The causes of valvular heart disease include
congenital malformation and rheumatic disease which is secondary to bacterial infection.
Congenital valve disease affects about 2% of the general population.2, 3 The disease may
manifest as valvular stenosis, an obstruction of outflow, or as regurgitation, a defective
closure resulting in backward flow. Congenital valve malformations tend to cluster in
families among both close and distant relatives, suggesting a genetic component of this
disease.4, 5 However, molecular mechanisms responsible for congenital valve disease are
still not fully understood.
Nitric oxide synthase (NOS) enzymes convert L-arginine to L-citrulline and
produce nitric oxide (NO), a signaling molecule involved in a wide range of
physiological processes including apoptosis, angiogenesis, cell proliferation and
differentiation.6-8 Three distinct isoforms of NOS has been identified: neuronal NOS
(NOS1), inducible NOS (NOS2) and endothelial NOS (NOS3). The expression of NOS3
starts around E9.5 during early mouse embryonic heart development.9 This expression
remains high until E13.5. By E14.5, the levels of NOS3 expression decrease in both atria
and ventricles. After E19.5 low NOS3 levels are still detectable and this level of NOS3
expression in the myocardium remains into adulthood.9
The atrioventricular (AV) valve development starts at E9 with the formation of
endocardial cushions. A subpopulation of endocardial cells of the endocardial cushion
undergoes endothelial-to-mesenchymal transition (EndMT) and provides the primary cell
source for the development of AV valves.10 Proliferation of the mesenchymal cells and
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matrix deposition extend the cushions into the cardiac lumen and form primordia of each
distinct valve. This is followed by elongation and remodeling of the valve primordia,
which leads to the gradual formation of valves by E15.11 The valves continue to grow and
remodel throughout heart development and well after birth.12-14 EndMT is a crucial
process for proper formation of AV valves.15 Transforming growth factor (TGFβ), bone
morphogenetic protein (BMP)-2, and Snail1 have been shown to promote EndMT and
valve formation.16 We have shown that NOS3 is important for embryonic heart
development.17 Deficiency in NOS3 leads to congenital septal defect, bicuspid aortic
valves and coronary artery malformation.18-20 In addition, Notch-dependent NOS3
activation has been shown to promote EndMT in the developing atrioventricular (AV)
canal from E9 to E11.5 via activation of the PI3-kinase/Akt pathway.21 The temporal
expression pattern of NOS3 peaks during AV valve formation along with its role in
EndMT, suggesting that NOS3 may participate in the development of the AV valves.
However, the role of NOS3 in the formation and functioning of AV valves has not been
studied. In the present study, we hypothesized that NOS3 promotes embryonic
development of AV valves via EndMT. To test this hypothesis, morphological changes
and functional competence of AV valves were studied in wild-type (NOS3+/+), NOS3-/and cardiac specific NOS3 overexpressing (NOS3Tg) mice. Furthermore, the role of
NOS3 in endocardial EndMT and signaling pathway critical to AV valve development
was also examined. Our study demonstrated that NOS3 promotes endocardial EndMT
and embryonic AV valve development.
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3.3

METHODS

3.3.1 Animals
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (NOS3+/+)
mice were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program
was carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was
performed by a polymerase chain reaction (PCR) method using genomic DNA prepared
from tail biopsies. A timed breeding program was carried out. Vaginal plugging was
monitored in the morning of each day and when plugged, was considered 0.5 days into
pregnancy. Embryonic hearts were collected at E10.5, E12.5, and postnatal day 0. The
investigation conforms to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication #85-23, revised 1996)
and the experimental protocols were approved by Animal Use Subcommittee at Western
University.
3.3.2 Generation of Human NOS3 Transgenic Mice
A new line of cardiac-specific mice overexpressing human isoforms of NOS3
(NOS3Tg) was generated.20 Briefly, human NOS3 complementary DNA was inserted into
the β-myosin heavy chain promoter expression vector 22 to permit the expression of
human NOS3 only during embryonic development and specifically in the heart. Our
previous studies have shown that the transgene is specifically expressed in the heart
during embryonic development.20 Genotypes were identified by PCR using genomic
DNA from tail biopsies.
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3.3.3 General Tissue Processing
Neonatal NOS3+/+, NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg mice were used for
analysis. Hearts were isolated and fixed in 4% paraformaldehyde, dehydrated, and
embedded in paraffin. Five micro-meter transverse serial sections were mounted onto
albumin/glycerin coated glass slides.
3.3.4 Immunohistochemistry and Immunofluorescence
Established protocols were used with minor modifications 18, 20, 23. Briefly, after
deparaffination and rehydration of the slides, microwave antigen retrieval was applied by
heating them for 10 min at 98°C in a citric acid buffer (0.01 M in aqua-dest, pH 6.0).
Inhibition of endogenous peroxidase was performed with a solution of 0.3% H2O2 in
phosphate buffered saline (PBS) for 30 min. The slides were incubated overnight with
either 1:500 anti-Snail1 (Abcam, USA). Next, the goat anti-rabbit secondary antibody
conjugated with biotin (1:200, Vector Laboratories, USA) was added for 60 min in PBS.
Subsequently, slides were incubated with ABC reagent (Vector Laboratories, USA) for
30 min. For visualization, the slides were incubated with 400 μg/ml 3-3’diaminobenzidin tetrahydrochloride (Sigma-Aldrich, USA) and 100 μL of 30% H2O2
dissolved in PBS for 10-15 min. Counterstaining was performed with 0.1% hematoxylin.
The size and length of AV valves were measured at the proximal (hinge) and distal
aspects of the leaflets as described previously.24
3.3.5 Three-Dimensional Reconstructions and Histological Analysis
Three-dimensional (3D) reconstructions of the heart and AV valves were
performed using Masson’s Trichrome stained serial sections of P1 hearts through the
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AMIRA® software (Template Graphics Software, USA) as previously described 20. AV
valve volumes were determined using the AMIRA® program.
3.3.6 Heart Function Measurements
Left ventricular (LV) and right ventricular ejection fraction and fractional
shortening were measured using the Vevo 2100 ultrasound imaging system (Visual
Sonics, Canada).20 Briefly, 2-dimensional images of the heart were obtained in short-axis
view using a dynamically focused 40 MHz probe. The M-mode cursor was positioned
perpendicular to the LV anterior and posterior walls. The LV internal end-diastolic
dimension (LVIDd) and LV internal systolic dimension (LVIDs) were measured from Mmode recordings. LV ejection fraction was calculated as: EF (%) = [(LVIDd)3 (LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%) = (LVIDdLVIDs)/LVIDd×100. The M-mode measurements of the left ventricular ejection fraction
and fractional shortening were averaged from 3 cycles. Both left and right atrial areas
were traced and calculated under the apical 4-chamber view in B-mode. AV valve E/A
ratio, regurgitation and flow pattern were measured through both color flow Doppler
recordings and pulsed-wave Doppler echocardiograms.25
3.3.7 Ex vivo Heart Cultures
E12.5 WT and NOS3-/- hearts were explanted and cultured in M199 medium
(Sigma-Aldrich, USA) supplemented with 10% FBS as previous described.20 Hearts were
stabilized for 2 hours prior to any treatment. Both WT and NOS3-/- hearts were beating
throughout the entirety of the experiment. WT and NOS3-/- hearts were treated with 100
µM 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) (Sigma-Aldrich, USA) and 2
mM 8-Bromo-cGMP (Sigma-Aldrich, USA), respectively for 6 hours. Some WT and
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NOS3-/- hearts were treated with recombinant TGFβ protein (10 ng/ml) for 18 hours.
Hearts were then collected and mRNA levels of Snail1, TGFβ and BMP2 were analyzed
by real time RT-PCR.
3.3.8 Real-time RT-PCR
Standard protocol was used as previous described.7, 18, 20, 23 Briefly, total RNA was
isolated from cultured fetal hearts with a RNA isolation kit (Qiagen, Canada). cDNA was
synthesized using M-MLV (Invitrogen, Canada) reverse transcriptase and random
primers (Invitrogen, Canada). Real-time PCR was conducted using SYBR Green PCR
Master Mix as per manufacturer's instructions (Eurogentec, USA). The oligonucleotide
primers used in this study are summarized in Online Supplementary Table 1. Samples
were amplified for 35 cycles using Eppendorf Real-Time PCR machine and analyzed
using cycle threshold (Ct) analysis. A ratio of target gene versus 28S rRNA was used to
determine the relative expression of Snail1, BMP2 and TGFβ.23
3.3.9 Measurement of cGMP
The cGMP levels in the heart were measured using an ELISA kit according to the
manufacturer’s instructions (ADI-900-014, Enzo Life Sciences, USA).26 Neonatal
NOS3+/+, NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg hearts were used for analysis. Briefly, 10
µg of protein lysates from the isolated hearts and standards were added to the cGMP
conjugated to alkaline phosphatase and an anti-cGMP antibody, and incubated for 2
hours at room temperature. This incubation allows the antibody to bind the cGMP in the
sample or conjugate in a competitive manner. After 3 washes, p-nitrophenyl phosphate
(pNpp) substrates were added and the plated and incubated for 1 hour at room
temperature. This incubation allows the catalysis of pNpp substrate by the alkaline
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phosphatase on the cGMP conjugate. The reaction was then stopped by tri-sodium
phosphate solution and the optical density was read at 405 nm. The amount of signal is
indirectly proportional to the amount of cGMP in the sample.
3.3.10 Endocardial Cushion Explant Culture
Endocardial cushion explants were cultured accordingly to methods previously
described with minor modifications.27 Briefly, E10.5 NOS3+/+ and NOS3-/- hearts were
planted on a 35 mm petri dish coated with 1 mg/ml collagen type I gel overnight for
attachment. After attachment, the hearts were treated with 100 µl of M199 supplemented
with 10% FBS and allowed 2 days for EndMT to occur. After 2 days, these hearts were
imaged under phase contrast microscopy (Observer D1, Zeiss, Germany). The number of
spindle-like mesenchymal cells was counted.
3.3.11 Statistical Analysis
Data are presented as mean ± SEM. Survival curves were created by the method
of Kaplan and Meier and compared by log-rank test. Unpaired Student’s t test was used
for 2 group comparisons. One way ANOVA followed by Student-Newman-Keuls test
was performed for multi-group comparisons. P<0.05 was considered statistically
significant.
3.4

Results

3.4.1 Deficiency in NOS3 impairs AV valve formation
Trichrome staining of mitral and tricuspid valves in NOS3+/+, NOS3-/-, NOS3Tg
and NOS3Tg;NOS3-/- mice at P0 is shown in Figure 3.1A-J. In NOS3-/- hearts, AV valves
were much smaller than those of other genotypes. The size of proximal (hinge) and distal
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aspects of the valve leaflets was measured as illustrated in Figure 3.1M. Quantitative
analysis of mitral and tricuspid valves show that the size (thickness) and length of the
proximal and distal leaflets were significantly smaller in the NOS3-/- compared with
NOS3+/+ hearts (P<0.05, Figure 3.1E-L, 3.2F, 3.3F). Cardiomyocyte-specific NOS3
overexpression (NOS3Tg;NOS3-/-) completely rescued these defects in the NOS3-/- mice
(P<0.05, Figure 3.1D- F, 3.1J-L, 3.2F, 3.3F). To investigate whether the valvular defect
in the NOS3-/- animals is due to premature maturation, cell density in the valves was
measured.12-14 Our data showed that there was no significant difference in cell density in
mitral and tricuspid valves among all groups at P0 (Figure 3.2G and 3.3G). Furthermore,
the decrease in valve length was evident as early as E15.5 in both mitral and tricuspid
valves (Figure 3.4A-B). These data supports a developmental defect rather than
premature maturation of the AV valves in NOS3-/- mice.
The volume of the mitral and tricuspid valves was determined through 3D
reconstructions (Suppl. Figure 3.2A-E and 3.3A-E). The normal mitral valve of NOS3+/+
mice had 2 distinct leaflets. However, the overall volume of the mitral valve was
significantly smaller in NOS3-/- compared with NOS3+/+ mice, which was restored by
cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS3-/- mice (P<0.01,
Figure 3.2A-E). The tricuspid valve of NOS3+/+ mice had 3 distinct leaflets. Similar to
the findings in the mitral valve, the overall volume of tricuspid valve was significantly
decreased in NOS3-/- compared with NOS3+/+ mice, which was completely rescued by
cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS3-/- mice (P<0.01,
Figure 3.3A-E).
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Figure 3.1 Malformation of mitral and tricuspid valves in NOS3-/- mice, which are
rescued by cardiomyocyte-specific NOS3 overexpression (NOS3Tg;NOS3-/-).
Representative tissue sections with Masson’s Trichrome staining of mitral (A-D) and
tricuspid (G-J) valves in WT, NOS3-/-, NOS3Tg and NOS3Tg;NOS3-/- mice at P0. (E and
F) Quantification of mitral valve size. (K and L) Quantification of tricuspid valve size.
Anterior and posterior leaflets represent the valve leaflet closer to the septum and
ventricular free wall, respectively. (M) Valve size was measured at the proximal (hinge)
and distal aspects of the leaflets. White arrows represent proximal and distal
measurements. Black arrow points to the hinge of the valve. Scale bar = 60 µm. Data are
mean  SEM from 5-8 mice per group. *P<0.05 vs. WT (NOS3+/+), †P<0.05 vs. NOS3-/mice.
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Figure 3.2 Three-dimensional (3D) reconstructions of mitral valve of WT, NOS3-/-,
NOS3Tg and NOS3Tg;NOS3-/- mice at P0 (A-D). 3D reconstructions were made by putting
together images taken from approximately 100 serial heart sections at 5 µm using Amira
software. Valve locations in the heart are shown. Whole heart images are frontal views of
the heart. Isolated valve images are viewed from the left atrium into the left ventricle. E.
Quantitative analysis of mitral valve volume. Data are mean  SEM from 5 mice per
group. F. Quantification of mitral valve length in P0 hearts. G. Quantification of mitral
valve cell density in P0 hearts. *P<0.01 vs. WT. †P<0.01 vs. NOS3-/- mice. Tg;-/- and
Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively.
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Figure 3.3 3D reconstructions of tricuspid valve of WT, NOS3-/-, NOS3Tg and
NOS3Tg;NOS3-/- mice at P0 (A-D). 3D reconstructions were made by putting together
images taken from approximately 100 serial heart sections at 5µm using Amira software.
Valve locations in the heart are shown. Whole heart images are frontal views of the heart.
Isolated valve images are viewed from the right atrium into the right ventricle. E.
Quantitative analysis of tricuspid valve volume. F. Quantification of tricuspid valve
length in P0 hearts. G. Quantification of tricuspid valve cell density in P0 hearts. Data are
mean  SEM from 5 mice per group. *P<0.01 vs. WT. †P<0.01 vs. NOS3-/- mice. Tg;-/and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively.
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Figure 3.4 Mitral and tricuspid valve length measurements at E15.5. A. Length of
anterior and posterior leaflets of the mitral valve. B. Length of anterior and posterior
leaflets of the tricuspid valve. Data are mean  SEM from 5 mice per group. *P<0.05 vs.
WT. †P<0.05 vs. NOS3-/- mice. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg,
respectively.
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3.4.2 Regurgitation of AV valves in NOS3-/- mice
In order to investigate the functional significance of AV malformation in NOS3-/mice, echocardiographic imaging analysis was performed on NOS3+/+, NOS3-/-, NOS3Tg
and NOS3Tg;NOS3-/- mice at P0 live animals. Color flow Doppler recordings showed
backflow of mitral (Figure 3.5A) and tricuspid (Figure 3.6A) valves in NOS3-/- mice.
Using pulsed-wave Doppler, the backflow velocity and duration were quantified. The
velocity and duration of backflow in mitral (Figure 3.5C-D) and tricuspid valves (Figure
3.6C-D) were significantly increased in NOS3-/- compared with NOS3+/+ mice (P<0.05).
Cardiomyocyte-specific NOS3 overexpression completely rescued these abnormalities in
the NOS3-/- animals (Figure 3.5A-D, 3.6A-D).
AV valve regurgitation could potentially result in lowered cardiac function. To this end,
ejection fraction and fractional shortening were determined. Our data showed that
ejection fraction and fractional shortening of both left and right ventricles were
significantly decreased in NOS3-/- compared with NOS3+/+ mice (P<0.05, Figure 3.7A-D).
Cardiomyocyte-specific NOS3 overexpression in NOS3-/- mice restored ejection fraction
and fractional shortening in both left and right ventricles to levels comparable to the
NOS3+/+ mice. Additionally, we assessed the E/A ratio of the AV valves, which
represents diastolic function or the ability of the blood to flow from the atria to the
ventricles. E represents the passive filling of blood from atria to ventricles, whereas A
represents the active contraction of the atria that pumps blood to the ventricles. Our
results showed that no significant difference was observed between all groups in E/A
ratios or the ability of the blood to flow from the atria to the ventricles (Figure 3.7E-F).
Lastly, as a consequence of AV valve regurgitation, the size of atria would increase due
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to the backward flow from the ventricles. As expected, the size of both left and right
atrium was significantly increased in the NOS3-/- compared with NOS3+/+ mice, which
was restored in NOS3Tg;NOS3-/- mice at P0 (P<0.05, Figure 3.7G-H).
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Figure 3.5 Regurgitation of mitral valve in NOS3-/- mice at P0. Backflow of mitral valves
was determined by color (A) and pulsed-wave (B) Doppler echocardiography. Backflow
during systole is indicated by arrows. WT mice had no backflow in mitral valves.
However, NOS3-/- mice showed significant mitral valve backflow. (C-D) Quantification
of mitral valve regurgitation. Significant regurgitation was observed in NOS3-/- mice,
which were rescued by cardiomyocyte-specific NOS3 overexpression. Data are mean 
SEM from 6-7 mice per group. *P<0.01 vs. all other groups. +/+, WT; -/-, knockout; Tg,
transgenic. Tg;-/- and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively.
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Figure 3.6 Regurgitation of tricuspid valve in NOS3-/- mice at P0. Backflow of tricuspid
valves was determined by color (A) and pulsed-wave (B) Doppler echocardiography.
Backflow during systole is indicated by arrows. WT mice had minor backflow in
tricuspid valves. However, NOS3-/- mice showed marked tricuspid valve backflow. (C-D)
Quantification of tricuspid valve regurgitation. Significant regurgitation was observed in
NOS3-/- mice, which were rescued by cardiomyocyte-specific NOS3 overexpression. Data
are mean  SEM from 6-7 mice per group. *P<0.01 vs. WT (NOS3+/+), †P<0.01 vs.
NOS3-/-. +/+, WT; -/-, knockout; Tg, transgenic. Tg;-/- and Tg;+/+ indicate NOSTg;NOS3/-

and NOS3Tg, respectively.
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Figure 3.7 Cardiac function determined using echocardiography at P0. (A-D) Both left
and right ventricular ejection fraction and fractional shortening were significantly
decreased in the NOS3-/- mice compared with WT controls, which were rescued by
cardiomyocyte-specific NOS3 overexpression. (E-F) E/A ratio showed no significant
difference between all groups. (G-H) Left and right atrial size was significantly increased
in NOS3-/- mice compared with WT controls, which was rescued by cardiomyocytespecific NOS3 overexpression. Data are mean  SEM from 6-7 mice per group. *P<0.05
vs. WT (NOS3+/+), †P<0.05 vs. NOS3-/-. +/+, WT; -/-, knockout; Tg, transgenic. Tg;-/and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively.
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3.4.3 Snail1+ and total mesenchymal cells are decreased in the endocardial cushion
of NOS3-/- mice
Snail1 is a zinc finger transcriptional repressor, which inhibits adhesion molecule
E-cadherin expression and induces EndMT during embryonic development.28, 29
Therefore, Snail1 is an excellent marker of mesenchymal cells in the AV cushion. To
further elucidate the role of NOS3 in early AV valve formation, immunostaining of
Snail1 was performed and Snail1+ mesenchymal cells were quantified at E10.5 and E12.5.
Our data showed that while there were no significant changes in the overall size and
volume of the AV endocardial cushion at E10.5 and E12.5 (Figure 3.8D, G), the number
of Snail1 positive mesenchymal cells (brown staining in histology) and total number of
mesenchymal cells within the endocardial cushion were significantly decreased in the
NOS3-/- compared with NOS3+/+ hearts at E10.5 and E12.5 (P<0.05, Figure 3.8A-C, E, F).
Since reduction of mesenchymal cells in NOS3-/- hearts was seen at both E10.5 and E12.5,
the rest of the analysis was done in E12.5 hearts. Three-dimensional reconstruction of
Snail1 expression (labeled in red) in the NOS3+/+ mice showed Snail1 completely covered
the outer part of the endocardial cushion, which represents cells that are actively
undergoing EndMT (Figure 3.8A). However, in the NOS3-/- mice, only limited parts of
the endocardial cushion were Snail1 positive, indicating the EndMT process is impaired
in the NOS3-/- mice. The number of Snail1 positive and total mesenchymal cells was
completely restored by cardiac specific NOS3 overexpression (P<0.05, Figure 3.8A-C, E,
F).
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Figure 3.8 EndMT is impaired in the AV cushion of NOS3-/- hearts at E12.5. (A) 3D
reconstructions (Left and middle columns, Red for Snail1+ cells; Grey for cushion) and
representative Snail1 immunostaining (Right column, Brown staining indicates Snail1+
cells). Scale bar = 50 µm. (B) Quantification of Snail+ mesenchymal cell volume from
3D reconstructed AV cushions. (C) Total number of mesenchymal cells from E12.5
cushions was quantified. (D) Quantification of endocardial cushion size at E12.5 from 3D
reconstructions. (E) Quantification of Snail1+ endocardial cushion mesenchymal cells at
E10.5 from 3D reconstructions. (F) Quantification of total endocardial cushion
mesenchymal cells at E10.5. (G) Quantification of endocardial cushion size at E10.5
from 3D reconstructions. N= 3-4 mice per group. *P<0.05 vs. NOS3+/+ or WT control.
†P<0.05 vs. NOS3-/- or NOS3-/- control.
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3.4.4 cGMP signaling is decreased in NOS3-/- hearts
cGMP, a downstream signaling molecule of NOS3, was significantly decreased in
the NOS3-/- compared with NOS3+/+ hearts at P0 (P<0.05, Figure 3.9A). Cardiac specific
NOS3 overexpression in NOS3-/- mice increased myocardial cGMP to similar levels of
NOS3+/+ mice (Figure 3.9A). To elucidate the precise role of NOS3 in regulating Snail1
expression, ex vivo E12.5 heart cultures were employed. The TGFβ and BMP family
proteins are critical to AV valve development.15, 16 Treatment with ODQ, a soluble
guanylyl cyclase inhibitor significantly decreased TGFβ1, BMP2 and Snail1 mRNA
expression in the WT hearts (P<0.05, Figure 3.9B-D). Conversely, NOS3-/- hearts treated
with 8-Bromo-cGMP, a cGMP analog showed a significant increase in TGFβ1, BMP2
and Snail1 mRNA levels (P<0.05, Figure 3.9B-D). These data suggest that NOS3
regulates the expression of TGFβ1, BMP2 and Snail1 through a cGMP-dependent
pathway. To investigate if TGFβ regulates Snail1 signalling, recombinant TGFβ is used
to treat WT and NOS3-/- hearts. Our data showed that recombinant TGFβ protein
treatment significantly increased Snail1 expression in both WT and NOS3-/- hearts
(P<0.05, Figure 3.9E).
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Figure 3.9 cGMP regulates expression of Snail1, TGF and BMP2 in E12.5 hearts. (A)
cGMP levels in P0 hearts. (B-D) E12.5 ex vivo heart cultures. Cultured WT and NOS3-/hearts were treated with ODQ (100 µM), a soluble guanylate cyclase inhibitor, or 8-BrcGMP (2 mM), a cGMP analog for 6 hrs. Snail1, TGF and BMP2 mRNA levels were
determined by real-time RT-PCR. (E) E12.5 ex vivo heart cultures from WT and NOS3-/mice were treated with recombinant TGFβ protein (10 ng/ml). TGF mRNA levels were
determined by real-time RT-PCR. N=6 hearts per group for C-G. *P<0.05 vs. NOS3+/+ or
WT control. †P<0.05 vs. NOS3-/- or NOS3-/- control.
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3.4.5 EndMT is impaired in NOS3-/- endocardial cushions
To further confirm the role of NOS3 in endocardial EndMT, endocardial cushions
from E10.5 embryos were dissected and cultured on collagen type I gel. Collagen type I
gel was chosen to simulate the in vivo conditions of the cardiac jelly, which the
mesenchymal cells migrate into. After 2 days of culture, cells that underwent EndMT
exhibited spindle-like morphology and migrated from the endocardial cushion into the
collagen gel. Results showed the total number of mesenchymal cells was significantly
decreased in NOS3-/- compared to NOS3+/+ explants (P<0.05, Figure 3.10A-B),
suggesting NOS3 promotes endocardial EndMT.
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Figure 3.10 Atrioventricular (AV) endocardial cushion explant culture from E10.5
NOS3-/- and WT mice. (A) Spindle shaped mesenchymal cells (arrows) were formed after
24 hours of culture. Lower panel is an enlargement of the boxed area. (B) The total
number of mesenchymal cells per mm of explant cushion tissue was significantly
decreased in NOS3-/- compared to WT explants. Data are mean  SEM from 6 explants
per group. *P<0.05 vs. WT. Black scale bar = 100 µm, white scale bar = 10 µm. (C)
Proposed signaling pathway by which NOS3 promotes endocardial EndMT and AV
valve development. Dash lines represent signalling pathways shown by others.
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3.5

DISCUSSION
The present study was carried out to examine the role of NOS3 in AV valve

formation. We demonstrated for the first time that deficiency in NOS3 leads congenital
AV valve defects. Additionally, lack of NOS3 also impairs endocardial EndMT.
Furthermore, we showed that cardiomyocyte-specific NOS3 overexpression mice
completely rescued these defects in NOS3-/- mice. In order to assess the functional
significance of these defects, echocardiography was carried out on P0 live animals. Our
data showed severe regurgitation of both mitral and tricuspid valves in the NOS3-/- mice.
This phenotype was accompanied by reduced ejection fraction and fractional shortening
and increased atrial size. Moreover, cardiomyocyte-specific NOS3 overexpression
completely rescued these phenotypes. Our study suggests that NOS3 promotes
endocardial EndMT and embryonic development of AV valves (Figure 3.10C).
The main function of AV valves is to prevent blood form flowing backwards from
the ventricles to the atria during systole. Clinically, AV valve regurgitation can present in
various forms depending on etiology and severity.29 In the case of acute AV valve
regurgitation, heart failure and cardiogenic shock may occur leading to death as a result
of backflow from the ventricles and volume overload.30, 31 Severe AV valve regurgitation,
decreased heart dysfunction and increased in atrial size were observed in the NOS3-/mice. These phenotypes highly resemble congenital AV valve insufficiency, a clinical
condition with infants born with shortened or a complete lack of AV valves.32, 33
However, it is possible that that mitral valve prolapse may also play a role in AV valve
regurgitation seen in the NOS3-/- mice. NOS3-/- mice have coronary artery malformation
which could lead to cardiac ischemia and papillary muscle dysfunction.20 This could
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cause AV valve regurgitation. Although we cannot eliminate the possibility of mitral
valve prolapse, we saw AV valve regurgitation accompanied by a phenotypic change of
the AV valve structure. Therefore, our data support the notion that AV valve
regurgitation is likely a result of AV valve insufficiency. Mitral valve insufficiency is
often associated with other cardiac defects such as atrial septal defects (ASD), ventricular
septal defects (VSD), aortic valve insufficiency and tricuspid valve insufficiency.34
Tricuspid valve insufficiency, also known as tricuspid valve regurgitation, is also
associated with congenital cardiac defects such as VSD and mitral valve regurgitation.32
These accompanying cardiac defects are very similar to phenotypes seen in the NOS3-/mice providing an excellent animal model to study AV insufficiency.18, 19 Clinically, AV
valve insufficiency is a serious congenital heart disease with very limited options other
than invasive open-chest surgery. The molecular mechanisms underlying this disease are
still largely unknown. The present study on the role of NOS3 in AV valve formation
provides a possible mechanistic explanation to AV valve insufficiency.
Snail1, a zinc finger transcriptional repressor, is critical to induction of EndMT
during embryonic development.28 Snail1 knockout mice have defects in mesoderm
formation and die around E7.5.35 In addition, deletion of Snai1 specifically in the epiblast
results in death by E9.5 due to multiple vascular defects and increased apoptosis.36 To
investigate the role of NOS3 in early AV valve formation, in vivo Snail1 expression and
ex vivo endocardial EndMT were assessed. Our results showed the number of Snail1
positive mesenchymal cells and total number of endocardial cushion mesenchymal cells
were significantly decreased in NOS3-/- compared with NOS3+/+ hearts at E10.5 and
E12.5 (Figure 3.5). In addition, the total number of mesenchymal cells from E10.5
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endocardial cushion cultures was significantly decreased in NOS3-/- explants (Figure 3.7A,
B). These data show a reduction of endocardial EndMT in the NOS3-/- mice leading to
malformation of mitral and tricuspid valves.
TGFβ is expressed at high levels in AV mesenchyme during cushion formation
and the critical to EndMT and AV valve development.37 Blockade of TGFβ2 by
neutralizing antibody inhibits EndMT in mouse heart explants and TGFβ2 knockout mice
show valvular defects.27, 38 BMP2 is also important for AV cushion EndMT. Nkx2.5
mediated deletion of BMP2 reduced AV cushion formation and cellularity.39 A classic
pathway by which NO mediates its biological function is through cGMP-dependent
protein kinase G (PKG) signaling.40 In this regard, NO has been shown to upregulate
TGFβ1 and BMP2 via PKG dependent pathway.41-43 In order to study the molecular
mechanism by which NOS3 promotes endocardial EndMT and AV valve development,
ex vivo E12.5 heart cultures were carried out to investigate the role of NO/cGMP
signaling in the expression of TGFβ1, BMP2 and Snail1. We showed that inhibition of
guanylate cyclase decreased TGFβ1, BMP2 and Snail1 expression in the WT hearts while
treatment with 8-Bromo-cGMP increased TGFβ, BMP2 and Snail1 mRNA levels in the
NOS3-/- hearts. These findings indicate that NOS3 acts as an upstream regulator of
TGFβ1, BMP2 and Snail1 through a cGMP-dependent pathway. Notably, TGFβ1 and
BMP are able to induce Snail1expression.15, 16 To this end, we showed that recombinant
TGFβ treatment significantly increased Snail1 expression in both WT and NOS3-/- hearts.
Taken together, our data suggest that cGMP production from NOS3 upregulates TGFβ
and BMP2, and promotes Snail1 expression and EndMT, leading to normal AV valve
development (Figure 3.10C).
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In summary, endocardial EndMT, an important process required for
valvulogenesis is impaired in NOS3-/- mice at E10.5 and E12.5, leading to malformation,
insufficiency and regurgitation of AV valves at P0. We anticipate that these new insights
into the mechanisms of AV valve development may lead to therapeutic strategies in the
prevention and possibly treatment of AV valve insufficiency.
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4.1

CHAPTER SUMMARY

Aims: Spontaneous aortic valve thrombosis is an extremely rare event but its underlying
mechanisms are still largely unknown. NO produced from NOS3 maintains endothelial
cell integrity and inhibits platelet aggregation. We aimed to study the role of NOS3 in
maintaining normal function and morphology of the aortic valve in adult life and aging.
We hypothesized that deficiency in NOS3 leads to spontaneous aortic valve thrombosis,
calcification and dysfunction in aging mice.
Methods and Results: At 12 months old, 72% (13/18) of NOS3-/- mice showed severe
spontaneous aortic valve thrombosis compared with WT mice (0/12). When platelets
were incubated with explanted aortic valves, platelet adhesion and aggregation to the
NOS3-/- valves were significantly higher compared with the WT controls. Additionally,
significant regurgitation of the aortic valve during systole was observed using
-/-

echocardiography in the NOS3 but not in WT mice. Furthermore, NOS3 deficiency
resulted in significant aortic valve stenosis, calcification and fibrosis. In ex-vivo aortic
valve interstitial cell cultures, inhibition of NOS by L-NAME increased calcification in
WT valves. In contrast, NO donor DETA-NO significantly inhibited calcification in
NOS3-/- valves.
Conclusion: Deficiency of NOS3 results in spontaneous aortic valve thrombosis,
calcification and stenosis. Our study suggests that NOS3 is pivotal in maintaining the
normal structure and function of the aortic valve in adulthood and aging.

130

4.2

INTRODUCTION
Valvular heart disease (VHD) affects over 2.5% of the general population. This

number dramatically increases to more than 13.3% of individuals over the age of 75.1, 2
Over the next 25 years, world population statistics project that there will be a doubling of
population in individuals between the age of 75 to 84.1 By this projection, individuals
over the age of 75 affected by VHD will double in the next 25 years. VHD can present in
many forms, one of which is the formation of a thrombus on the aortic valve.3, 4 The
spontaneous formation of a thrombus on the aortic valve is extremely rare in humans with
only less than a dozen of case reports in the literature.3-12 Although most of the cases
were patients with tricuspid aortic valves, one case showed spontaneous aortic valve
thrombosis was a result of calcific bicuspid aortic valve.5 However, aortic valve
thrombosis is extremely dangerous, as it could lead to embolization, and subsequent
cerebrovascular events such as stroke, myocardial infarction and death.3, 5-7, 11
Thrombosis is formed via adhesion and aggregation of platelets at the site of tissue injury
followed by fibrin clot formation. Many factors have been identified to be important
inhibitors of platelet activation and aggregation, such as apyrase, prostaglandin I2 and
nitric oxide (NO).13, 14 In addition, thrombosis formation can also be inhibited via
inhibitors of coagulation cascade such as thrombomodulin, tissue factor pathway
inhibitor (TFPI) and anti-thrombin III.15, 16 To our knowledge, spontaneous aortic valve
thrombosis has never been studied in an animal model.
Endothelial nitric oxide synthase (NOS3) belong to a family of enzymes known as
nitric oxide synthases (NOS). NOS catalyze the reaction of L-arginine and NADPH
producing NO. NO is a fast acting gaseous signaling molecule that is involved in many
131

physiological processes including apoptosis, angiogenesis, cell proliferation and
differentiation.17-19 20 NOS3 is important in maintaining normal cardiovascular function
including vasodilation, inhibition of inflammation and vascular smooth muscle
proliferation, stimulation of angiogenesis and recruitment of endothelial progenitor
cells.21 In pathophysiology, NOS3 polymorphism is associated with increased risk for
cardiovascular disease, increased incidence of congenital heart disease,
hypercholesterolemia, hypertension, diabetes and atherosclerosis.21
Spontaneous thrombosis of aortic valve can be seen in patients with hypercoagulative state such as polycythemia or systemic lupus erythematosus with anticardiolipin antibodies.22, 23 In addition, excessive valvular damage such as in the case of
calcific aortic valve stenosis (CAVS) may induce thrombosis.5, 11 CAVS is the most
common valvular disease.1 CAVS is characterized by progressive narrowing of the aortic
valve resulting in aortic stenosis, calcification and thickening of the aortic valves and
aortic valve regurgitation.24 Although calcified aortic valve has been associated with
normal aging and valve degeneration, recent studies suggest that CAVS can be attributed
to a genetic origin. Mutations in Notch1, an important factor that is involved in many
developmental processes, has been shown to cause aortic valve disease similar to
CAVS.25 Notch1 functions by repressing the activities of Runx2, a central transcriptional
regulator in osteoblast cell fate.25 Importantly, NOS3 has been shown to act upstream of
Notch1 in aortic valve interstitial cells cultured in vitro by altering Notch1 intracellular
domain nuclear localization. 26 These findings suggest NOS3 may play a crucial role in
aortic valve disease. The aim of our current study was to investigate the role of NOS3 in
normal maintenance of aortic valve function and its role in aortic valve thrombosis and
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calcification. We hypothesized that deficiency in NOS3 leads to spontaneous aortic valve
thrombosis and calcification in the adult mice.
4.3

METHODS

4.3.1 Animals
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (WT) mice
were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program was
carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was performed
by a polymerase chain reaction (PCR) method using genomic DNA prepared from tail
biopsies. All procedures involving mouse husbandry and manipulation were in
accordance with the guidelines of the Canadian Council of Animal Care and approved by
the Animal Use Subcommittee at the University of Western Ontario, Canada.
4.3.2 General Tissue Processing
WT and NOS3-/- mice were used for analysis. Hearts were isolated and fixed in 4%
paraformaldehyde, dehydrated, and embedded in paraffin. Five micro-meter transverse
serial sections were mounted onto albumin/glycerin coated glass slides.
4.3.3 Immunohistochemistry and Immunofluorescence
After deparaffination and rehydration, the slides were incubated for 3 minutes
with 1% Sirius red solution for fibrosis, Mason’s Trichrome staining kit for collagen and
muscle. Counterstaining was performed with 0.1% hematoxylin (Merck, Germany).
Immunofluorescence was done using established protocols were used with minor
modifications.27-29 Briefly, after deparaffination and rehydration of the slides, microwave
antigen retrieval was applied by heating them for 10 min at 98°C in a citric acid buffer
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(10 mM in aquadest, pH 6.0). The slides were incubated overnight with either 1:100 antiRunx2 (Santa Cruz, USA), 1:100 anti-E-selectin (Biotech, USA). Next, the goat antirabbit secondary antibody conjugated with GFP (1:1000, Vector Laboratories, USA) was
added for 60 min in PBS. Finally, 0.1% DAPI solution was used to stain nuclei.
4.3.4 Heart Function Measurements
Left ventricular (LV) and right ventricular ejection fraction and fractional
shortening were measured using the Vevo 2100 ultrasound imaging system (Visual
Sonics, Canada). Briefly, 2-dimensional images of the heart were obtained in short-axis
view using a dynamically focused 40 MHz probe. The M-mode cursor was positioned
perpendicular to the LV anterior and posterior walls. The LV internal end-diastolic
dimension (LVIDd) and LV internal systolic dimension (LVIDs) were measured from Mmode recordings. LV ejection fraction was calculated as: EF (%) = [(LVIDd)3 (LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%) = (LVIDdLVIDs)/LVIDd×100. The M-mode measurements of the left ventricular ejection fraction
and fractional shortening were averaged from 3 cycles. Aortic valve regurgitation and
flow pattern were measured in both color flow Doppler recordings and pulsed-wave
Doppler echocardiograms.
4.3.5 Platelet Adhesion and Aggregation on Aortic Valves
Aortic valves were dissected from WT and NOS3-/- 12 months old mice and
cultured in M199 medium (Sigma-Aldrich, USA). Separately, the platelets were isolated
from the same animals and treated with a Calcein dye (Life Technologies, Canada) for 15
minutes under room temperature. The aortic valves were then treated with WT or NOS3-
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platelets for 1 hour at 37ºC. After the incubation period, the aortic valves were imaged

under fluorescence microscope (Observer D1, Zeiss, Germany).
4.3.6 Aortic Valve Interstitial Cell Cultures
WT and NOS3-/- aortic valves were explanted from 9-12 week old adult mice and
cultured in M199 medium (Sigma-Aldrich, USA). WT and NOS3-/- hearts were planted
on a 35 mm petri dish coated with 1 mg/ml collagen type I gel for 6 days for attachment
and to allow valve mesenchymal cells, which are valve interstitial cells (VICs) to migrate.
After attachment, the aortic valves were treated with 300 µl of osteo-differentiation
media along with L-NAME in WT aortic valves and DEAT-NO in NOS3-/- aortic valves.
After 18 days of culture, cells were stained with 0.5% Alizarin red for calcification and
imaged under phase contrast (Observer D1, Zeiss, Germany). The number of calcified
mesenchymal cells was counted.
4.3.7 Real Time RT-PCR
Total RNA was isolated from aortic valves of 12 months adult WT and NOS3-/mice with RNA isolation kit (Qiagen, Canada). cDNA was synthesized using M-MLV
(Invitrogen, Canada) reverse transcriptase and random primers (Invitrogen, Canada).
Real-time PCR was conducted using SYBR Green PCR Master Mix as per
manufacturer's instructions (Eurogentec, USA). Samples were amplified for 35 cycles
using Eppendorf Real-Time PCR machine. The expression levels of Notch1, Runx2, Sp7
and β catenin in relation to 28S rRNA as a loading control were obtained.
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4.3.8 Statistical Analysis
Data are presented as mean ± SEM. Unpaired Student’s t test was used for 2
group comparisons. One way ANOVA followed by Newman-Keuls test was performed
for multi-group comparisons. P<0.05 was considered statistically significant.
4.4

Results

4.4.1 Severe spontaneous aortic valve thrombosis in NOS3-/- mice
Severe spontaneous aortic valve thrombosis was observed in NOS3-/- mice at 12
months old. Representative 3-D reconstructions of normal aortic valve of a WT mouse
and a thrombus on the aortic valve of a NOS3-/- mouse are shown in Fig. 4.1A. The
thrombus was positioned on the aortic side of the valve. Next, Masson’s trichrome
staining was used to assess WT and NOS3-/- aortic valves. WT mice showed normal cross
sectional aortic section with 3 distinct valve leaflets while 27% of NOS3-/- mice showed
only 2 valve leaflets with an enlarged aortic valve thrombosis (Fig. 4.1B). Hematoxylin
and eosin staining showed the formation of the thrombus originated from the aortic valve
(Fig. 4.1C). The thrombus had an intense eosin staining due to fibrin deposition (Fig.
4.1C). Quantitative analysis show 13/18 (72%) of NOS3-/- mice at 12 months of age had
spontaneous aortic valve thrombosis, in which 100% (5/5) bicuspid aortic valve and 62%
(8/13) tricuspid aortic valve NOS3-/- animals showed spontaneous aortic valve thrombosis.
None of the WT showed any aortic valve thrombosis (P<0.0001 Fig. 4.1D). Because of
hemodynamic changes, bicuspid aortic valve is associated with aortic valve calcification
and thrombosis in humans. To study the specific role of NOS3 on spontaneous
thrombosis and calcification, further analyses were done using mice with tricuspid aortic
valves.
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In order to study the role of NOS3 in platelet adhesion and aggregation on the
aortic valve, the aortic valves were explanted from WT and NOS3-/- 12 months old mice
and incubated with platelets. After 1 hour of incubation with the valves, the amount of
platelets on these valves was imaged and quantified. Our data show that WT and NOS3-/platelets were adhered significantly more to the NOS3-/- compared to the WT aortic
valves (Fig. 4.2A-B). Furthermore, NOS3-/- platelets were more adhesive to the NOS3-/valves compared to WT valves. In addition, platelets formed clumps on the NOS3-/- aortic
valves, indicating platelet aggregation (Fig. 4.2A).
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Figure 4.1 Severe spontaneous aortic valve thrombosis in NOS3-/- mice at 12 months old.
(A) 3-D reconstruction of aortic valves of WT and NOS3-/- mice. While WT mice have
three aortic valve leaflets, NOS3-/- mice show a bicuspid aortic valve with a spontaneous
aortic valve thrombosis (Marked in red). (B) Masson’s trichrome staining of WT and
NOS3-/- aortic valves. NOS3-/- mice show only 2 valve leaflets with an enlarged aortic
valve thrombosis. (C) Hematoxylin and eosin staining of a large thrombus on the aortic
valve from a NOS3-/- mouse. This is the same animal used in (B) to show that the origin
of the thrombus is from the aortic valves. (D) 72% of NOS3-/- mice but none of the WT
mice at 12 months old had spontaneous aortic valve thrombosis. *P<0.0001 vs. WT
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Figure 4.2 Platelet adhesion and aggregation on aortic valves. (A) WT and NOS3-/tricuspid aortic valves were dissected from 12 months old mice and marked with calcein
dye. These valves were then treated with WT or NOS3-/- platelets to assess platelet
aggregation. (B) Quantification of platelet aggregation on WT and NOS3-/- aortic valves
using fluorescence intensity. Data are mean  SEM from 4 mice per group. *P<0.05 vs.
corresponding WT aortic valve (AV) groups, †P<0.05 vs. NOS3-/- AV+WT platelets (Pl).
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4.4.2 Deficiency in NOS3 results in aortic valve regurgitation
C57BL/6 WT and NOS3-/- mice cardiac and aortic functions were measured at 3,
5, 9 and 12 months of age. Representative images showed normal systole blood flow in
WT and NOS3-/- mice at 12 months (Fig. 4.3A). While systole blood flow was normal,
diastolic blood flow showed severe aortic valve regurgitations in the NOS3-/- mice. This
was evident on both the color and pulsed wave Doppler recordings (Fig 4.3A-B). Further
quantifications showed that both regurgitation velocity and duration measured by pulsed
wave Doppler recordings were significantly increased (Fig 4.3C, D). Starting at 3 months,
29% of NOS3-/- mice showed mild to severe aortic valve regurgitation. This trend
continued at 5, 9 and 12 months with 33%, 33% and 37% of NOS3-/- mice showed aortic
valve regurgitation, respectively (Fig. 4.3E).
Cardiac functions measured by left ventricular ejection fraction and fractional
shortening were normal at 3, 5 and 9 months in WT and NOS-/- mice. However, left
ventricular ejection fraction and fractional shortening were significantly decreased at 12
months in NOS3-/- mice compare with age-matched WT controls (Fig. 4.4 A-C). In
addition, left ventricular anterior wall thickness during diastole and systole were
measured. Our data showed that there were no significant differences in the left
ventricular wall thickness at any time point of the study. To further assess the NOS3-/hearts, LV diameter were measure. Our data showed that there is no significant difference
between WT (2.16±0.035) and NOS3-/- (2.304±0.077) LV diameter in 12 months old mice.
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Figure 4.3 Severe aortic valve regurgitation in NOS3-/- mice. Regurgitation from aortic
valves was determined by color (A) and pulsed-wave (B) Doppler echocardiography.
Both WT and NOS3-/- mice show normal systolic outflow. However, NOS3-/- mice show
significant aortic valve regurgitation during diastole (A and B, red arrows). C-D.
Quantification of aortic valve regurgitation. Significant aortic regurgitation was observed
in NOS3-/- but not in WT mice. Data are mean  SEM from 6-7 mice per group. *P<0.01
vs. WT. E. The percentage of animals that showed aortic valve regurgitation at 12
months old.
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Figure 4.4 Assessment of cardiac function using echocardiography. (A) Representative
M-mode imaging showing decreased heart function in the NOS3-/- mice compared with
WT controls at 12 months. (B-C) Left ventricular fractional shortening and ejection
fraction at 3, 5, 9, and 12 months in NOS3-/- and WT mice. (D-E) Left ventricular wall
thickness during systole and diastole in WT and NOS3-/- mice from 3 to 12 months. Data
are mean  SEM from 5 mice per group. *P<0.05 vs. WT.
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4.4.3 Deficiency in NOS3 results in aortic valve fibrosis and thickening of the
aortic wall
To analyze collagen content, picro Sirius red staining was performed. NOS3-/aortic valve showed much stronger Sirius red staining than the WT at 12 months (Fig
4.5A, upper panel). Furthermore, the aortic wall in the NOS3-/- mice was thickened
compared with age-matched WT controls (Fig. 4.5A, lower panel). Quantitative analysis
showed that Sirius red staining intensity and aortic wall thickness were significantly
increased in the NOS3-/- mice compared with age-matched WT controls (Fig. 4.5B, C).
The total vascular smooth muscle cell numbers in the aortic wall were increased in NOS3/-

mice. However, cell density per mm2 was not significantly different between NOS3-/-

and WT controls (Fig. 4.5D). Moreover, the structure of the cells in the WT aortic wall
was organized and aligned, while in the NOS3-/-, the cells within the aortic wall was
disorganized and misaligned (Fig. 4.5A). Taken together, these results showed a
vulnerable and disorganized aortic wall structure in the NOS3-/- mice that is associated
hypertrophy of the aortic wall cells.
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Figure 4.5 Aortic valve fibrosis and aortic wall thickening in 12 months old NOS3-/mice. (A) Representative Sirius red and hematoxylin staining showing aortic fibrosis and
wall thickening, respectively. (B) Quantification of fibrosis staining intensity. (C)
Quantification of aortic wall thickness. (D) Quantification of cell density in the aortic
wall. Data are mean  SEM from 6-7 mice per group. *P<0.01 vs. WT.
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4.4.4 Deficiency in NOS3 results in endothelial cell activation/damage
Endothelial cell activation/injury may cause valvular damage and possibly aortic
valve thrombosis.5, 6 To assess whether endothelial cell activation is seen in the NOS3-/mice, sections were stained for the presence of E-selectin, which is an excellent marker
for endothelial cell activation.30, 31 Our data showed E-selectin expression significantly
increased in the NOS3-/- mice compared with WT mice (Fig. 4.6A). Further quantification
showed significantly increased number of activated endothelial cells in the NOS3-/- mice
compared with WT mice (Fig. 4.6B). To correlate this data with mRNA expression, Eselectin mRNA expression was determined in the WT and NOS3-/- mice. Similar to
protein staining, mRNA expression of E-selectin was significantly increased in the NOS3/-

mice compared with WT mice (Fig. 4.6C). Vascular cell adhesion molecule 1 (V-CAM)

and intercellular adhesion molecule 1 (I-CAM) are well known markers for endothelial
cell activation.31 Our data showed mRNA levels of both V-CAM and I-CAM were
significantly increased in the NOS3-/- mice compared with WT mice (Fig. 4.6D, E).
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Figure 4.6 Endothelial cell activation of the aortic valve in NOS3-/- mice. (A)
Representative histology images stained with E-selectin show endothelial cell activation
in the NOS3-/- mice. (B) Quantification of E-selectin+ endothelial cells in WT and NOS3-/mice. (C-E) Quantification of mRNA expression of well-known markers for endothelial
cell activation. Data are mean  SEM from 4-5 mice per group. *P<0.05 vs. WT.
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4.4.5 Deficiency in NOS3 results in severe aortic valve calcification
To assess aortic valve calcification, aortic valves from WT and NOS3-/- mice were
stained for the presence of Runx2, a marker of calcification (Fig. 4.7A). Our data showed
that Runx2 expression was significantly increased in the NOS3-/- mice compared to agematched WT controls (Fig. 4.7C). In addition, B-mode echocardiography images showed
brightened aortic valves, indicative of aortic valve calcification (Fig. 4.7A, red arrows).
Quantitative analysis of the brightness density of the aortic valves showed that there was
a significant increase in the NOS3-/- mice compared with age-matched WT controls (Fig.
4.7B).
Notch1 has been shown to be important in maintaining normal aortic valve function by
repressing the transcription of Runx2.25, 32 To examine if NOS3 regulates Notch1 and
Runx2 expression, mRNA was isolated from 12 months old WT and NOS3-/- aortic
valves. Our data showed that the Notch1 mRNA levels were significantly decreased in
the NOS3-/- mice compared with WT controls (Fig. 4.7D). Furthermore, the expression of
Runx2 was significantly increased in NOS3-/- mice compared with WT controls (Fig.
4.7E). To further confirm aortic valve calcification, we measured the expression of other
well-known markers of calcification including Alkaline phosphatase 1, Sp7 and β-catenin,
which were all significantly increased in the NOS3-/- mice compared with WT controls
(Fig. 4.7F, H-I). Sox9 is a negative regulator of Runx2. Our data showed that Sox9
mRNA levels were significantly decreased in the NOS3-/- mice compared with WT
controls (Fig. 4.7G).
To further study a protective effect of NOS3 against aortic valve calcification, exvivo cultures of aortic valve interstitial cells (VICs) were employed. The adult aortic
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valve was harvested and plated on collagen to allow VICs to migrate out. These cells
were then treated with an osteo-differentiation media in the presence of a nitric oxide
synthase inhibitor L-NAME or a NO donor DETA-NO for 18 days. The cultured VICs
were stained with Alizarin red to assess calcification. Our data showed that NOS3-/- VICs
exhibited significantly more calcification compared with WT cells (P<0.05, Fig. 4.8A-B).
Furthermore, when WT VICs were treated with osteo-differentiation media together with
L-NAME, calcification was significantly increased compared with controls. Finally,
when NOS3-/- aortic valve cells were treated with osteo-differentiation media in the
presence of DETA-NO, calcification was significantly decreased compared with controls
(P<0.05, Fig. 4.8A-B). Together, these data showed a key role of NO in inhibiting VIC
calcification.
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Figure 4.7 Severe aortic calcification in NOS3-/- mice. (A) Representative B-mode and
histology images stained with Runx2. (B) Calcification can be analyzed from the
brightness of the aortic valves in the B-mode echocardiography image (red arrows). (C)
Quantification of number of Runx2 positive cells in the aortic valve. (D-I) Quantification
of Notch, Runx2, AP1, Sp7, β-Catenin and Sox9 mRNA expression in WT and NOS3-/mice at 12 months old. Data are mean  SEM from 4-7 mice per group. *P<0.01 vs. WT

156

157

Figure 4.8 Effects of NO on calcification of cultured aortic valve interstitial cells (VICs).
(A) Representative images showing cultured VICs stained with Alizarin red for
calcification. WT VICs were treated the osteo-differentiation media and a nitric oxide
synthase inhibitor, L-NAME. NOS3-/- VICs were treated with osteo-differentiation media
and a nitric oxide donor, DETA-NO. (B) Quantification of Alizarin red positive cells. N=
3-4 cultures per group. *P<0.05 vs. WT Control. †P<0.05 vs.NOS3-/- Control.
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4.5

DISCUSSION
In the present study, we demonstrated for the first time that deficiency in NOS3

leads to spontaneous aortic valve thrombosis, regurgitation, and calcification and fibrosis.
Furthermore, we showed that the normal maintenance of aortic valves is dependent on
NOS3 produced NO, which inhibits VIC calcification. Additionally, we showed that
NOS3 regulates Notch1 and Runx2 signalling pathway to maintain normal aortic valve
function. Our study suggests that NOS3 plays a key role in the normal maintenance of
aortic valves in adulthood and aging.
Aortic valve thrombosis is extremely rare in the clinic. However, patients that
have this disease are often fatal due to thrombus breakage and subsequent embolism
resulting in stroke and myocardial infarction.5-7, 11 Increases in platelet aggregation are
associated with thrombus formation in patients with protein S deficiency or antiphospholipid syndrome.4, 7, 12 In the present study, the NOS3-/- aortic valves were more
prone to platelet adhesion and aggregation. Furthermore, NOS3-/- platelets had a
significantly higher aggregation compared to WT platelets on NOS3-/- aortic valves,
suggesting that NOS3 from both platelets and aortic valves contributes to inhibition of
platelet aggregation on aortic valves. Thus, lack of NOS3 from both platelets and aortic
valves may lead to aortic valve thrombosis in the aging NOS3-/- mice. Additional,
endothelial activation/injury can be a result of normal wear and tear during aging or
underlying disease condition such as calcification of the aortic valve.5, 6 Normally, NO
production from NOS3 protects endothelial cells from oxidative injury. 21 Additionally,
NOS3 promotes the recruitment of circulating endothelial progenitor cells, which
regenerate and repair the injured endothelium.33 However, in the NOS3-/- mice, these
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protective mechanisms are lost, resulting in thrombus formation. To our knowledge, this
is the first study that links NOS3 function to the spontaneous formation of an aortic valve
thrombus.
The function of aortic valves is to prevent backflow of blood from the outflow
tracts into the ventricles during diastole. The normal aortic valves are made up of 3
distinct cusps which evenly distribute the mechanical stress to the valve annulus and
aorta. When the even distribution of mechanical stress is disrupted such as in the case of
bicuspid aortic valves, part of the valve may have a higher stress and valvular endothelial
cells may get activated, leading to platelet aggregation and eventually the formation of
spontaneous aortic valve thrombosis. Previous studies have demonstrated that about 30%
of NOS3-/- animals show bicuspid aortic valve phenotype.34-36 In the present study, NOS3/-

mice with bicuspid aortic valve all developed spontaneous aortic valve thrombosis

(100%). However, in tricuspid aortic valve NOS3-/- animals, only 61.5% developed
spontaneous aortic valve thrombosis. It appears that mice with bicuspid aortic valves are
possibly more susceptible to the formation of spontaneous aortic valve thrombus.
However, due to a small sample size, there was no statistical difference in the incidence
of aortic valve thrombosis between these 2 groups of NOS3-/- mice. Experiments are
ongoing to increase the sample size of NOS3-/- mice. In CAVS, the valve cusps become
progressively fibrotic and calcified.37 This results in stiffened valves, reduced valve
movements and progressive valve narrowing resulting in aortic stenosis. If left untreated,
CAVS leads to left ventricular hypertrophy and eventually congestive heart failure and
death.38, 39 Aortic valve calcification plays a key role in the disease progression of
CAVS.40 Studies have shown that Notch1/Runx2 signalling limits aortic valve
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calcification.25 Notch1 is a transcription factor that is involved in many developmental
processes including liver, skeleton, heart, eye, face, kidney and vasculature.41 More
importantly, Notch1 mutations are associated with abnormal development of the aortic
valve including bicuspid aortic valve and aortic valve stenosis.25, 42 A reduction of Notch
signalling decreases epithelial to mesenchymal transition (EMT), which is necessary for
proper formation of aortic valves.43 In the adult aortic valve, Notch1 signalling activates
Hairy-related transcription, which physically interacts with Runx2, a master regulator of
osteoblast differentiation, and represses its transcriptional activity.44, 45 Activation of
Runx2 would result in osteoblast differentiation and calcification in the aortic valves. In
our study, NO inhibits osteogenic differentiation of VICs, consistent with previous
findings.46, 47 We further demonstrated that Notch1 expression is significantly decreased
in the NOS3-/- aortic valves compared with age-matched WT controls, suggesting that
NOS3 regulates Notch1 expression.26 Decreased Notch1 activity would increase Runx2
expression, leading to osteoblast differentiation and aortic valve calcification.
In summary, the present study demonstrates a pivotal role of NOS3 in limiting
aortic valve from thrombosis and calcification, and maintaining normal aortic valve
function. These beneficial effects NOS3 are likely mediated through the regulation of
Notch1 and Runx2. We believe this is an excellent animal model to study spontaneous
aortic valve thrombosis and the disease progression of CAVS. We anticipate that these
new insights into the role of NOS3 in maintaining normal aortic valve function may lead
to therapeutic strategies in the prevention and possibly treatment of spontaneous aortic
valve thrombosis and CAVS.
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CHAPTER 5
DISCUSSION

5.1

SUMMARY OF MAJOR FINDINGS AND DISCUSSION
The overall objective of this thesis was to investigate the regulatory role of NOS3

in the heart during embryonic development and adulthood. More specifically, I studied
the role of NOS3 in the embryonic development of coronary artery, the formation of
atrioventricular valves and the maintenance of adult aortic valves (Figure 5.1). To
achieve these goals, NOS3 genetic knockout animals were used and a novel cardiac
specific NOS3 overexpressing mouse was generated. Experimental approaches included
in vitro cell cultures, ex vivo heart cultures and in vivo animal studies as well as the use of
pharmacological inhibitors and adenoviral constructs.
In Chapter 2, I investigated the role of NOS3 in coronary artery development
(Figure 5.1). I demonstrated that neonatal NOS3-/- mice show severe abnormalities in
coronary arteries. Furthermore, as early as E15.5, coronary artery diameters, density and
volume were significantly decreased in the NOS3-/- compared with WT embryos. In order
to understand the molecular mechanism governing morphogenesis of the coronary
arteries, expression of transcription and growth factors critical to coronary development
was analyzed in E12.5 hearts. Interestingly, the expression of Gata4, VEGFa, bFGF and
EPO was down-regulated in the NOS3-/- compared with WT embryonic hearts.
Additionally, Wilm’s tumour-1 (Wt1), a transcription factor critical for EMT and
coronary artery formation, was also down-regulated and the number of epicardial derived
cells (EPDC) was decreased in the NOS3-/- hearts. These data suggest that NOS3 is
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critical to embryonic coronary artery development. It has been shown that NOS3
promotes proliferation in many cell types.1-3 For example, NOS3 promotes neonatal
cardiomyocyte proliferation by inhibiting TIMP-3 expression.1 NOS3 also promotes
migration of mesenchymal stem cells towards the heart.4 Therefore it is possible that not
only cell migration, but also cell proliferation of EPDCs is affected in the NOS3-/- mice.
Thus, a combination of decreased transcription and growth factors and decreased ability
of EPDC proliferation and migration into the myocardium may impair coronary artery
development in the NOS3-/- mice.
NOS3-/- mice show impaired coronary artery development partially due to
decreased EMT of the epicardium. EMT has also been shown to be crucial to
atrioventricular valve development in the embryonic heart. Thus, in Chapter 3, I
investigated the role of NOS3 in atrioventricular valve formation (Figure 5.1). I
demonstrated that for the first time that deficiency in NOS3 leads to impairment of
endocardial EMT and congenital AV valve defects. Furthermore, I showed that
cardiomyocyte-specific NOS3 overexpression mice completely rescued these defects in
NOS3-/- mice. In order to assess the functional significance of these defects,
echocardiography was carried out on P0 live animals. Our data showed severe
regurgitation of both mitral and tricuspid valves in the NOS3-/- mice. This phenotype was
accompanied by reduced ejection fraction and fractional shortening and increased atrial
size. Moreover, cardiomyocyte-specific NOS3 overexpression completely rescued these
phenotypes. To investigate the role of NOS3 in early AV valve formation, in vivo Snail1
expression and ex vivo endocardial EMT were assessed. Our results showed the
expression of Snail1 was significantly decreased in NOS3-/- compared with WT hearts at
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E12.5. In addition, explant culture of endocardial cushions from E10.5 mice showed that
the total number of mesenchymal cells was significantly decreased in NOS3-/- explants.
These data show a reduction of endocardial EMT in the NOS3-/- mice leading to
malformation of mitral and tricuspid valves. Our study suggests that NOS3 promotes
endocardial EMT and embryonic development of AV valves. To further understand the
underlying signaling mechanism, I showed that inhibition of guanylate cyclase decreased
TGFβ1, BMP2 and Snail1 expression in the WT hearts while treatment with 8-BromocGMP increased TGFβ, BMP2 and Snail1 mRNA levels in the NOS3-/- hearts. Both
TGFβ1 and BMP have the ability to stimulate Snail1expression.5,

6

To this end, we

showed that recombinant TGFβ treatment significantly increased Snail1 expression in
WT and NOS3-/- hearts compared with respective controls. Taken together, our data
suggest that cGMP production from NOS3 upregulates TGFβ and BMP2, and promotes
Snail1 expression and endocardial EMT, leading to normal AV valve development.
In Chapter 4, I investigated the role of NOS3 in the normal maintenance of aortic valve
function (Figure 5.1). I demonstrated for the first time that deficiency in NOS3 leads to
severe aortic valve thrombosis, regurgitation, aortic stenosis and aortic valve calcification
and thickening. Deficiency in NOS3 resulted in severe spontaneous aortic valve
thrombosis at 12 months old. Histological analysis showed the formation of a thrombus
originated from the aortic valve. Quantitative data showed that 72% of NOS3-/- mice at 12
months old had spontaneous aortic valve thrombosis. None of the WT showed any aortic
valve thrombosis. In order to test platelet aggregation of WT and NOS3-/- mice, an ex vivo
aortic valve culture explant was carried out. Our data showed that platelet aggregation
was significantly increased in NOS3-/- aortic valves. In addition, the NOS3-/- aortic valves
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showed clumping of platelets similar to that occurs in thrombus formation. Additionally,
severe aortic valve regurgitation was observed in the NOS3-/- mice. This phenotype
started at 3 months with 28.5% of NOS3-/- mice showing mild to severe aortic valve
regurgitation and continued at 5, 9 and 12 months with 33.3%, 33.3% and 36.8% of
NOS3-/- mice having aortic valve regurgitation, respectively. Furthermore, NOS3-/- mice
had aortic stenosis starting at 3 months old. As expected, this phenotype persisted at 5, 9
and 12 months. Moreover, the aortic wall in the NOS3-/- mice was thickened compared
with age-matched WT controls. To analyze calcification, aortic valves were harvested
from 12 months old WT and NOS3-/- mice and stained with Runx2, a marker of
calcification. My data showed that Runx2 staining was significantly increased in the
NOS3-/- mice compared with age-matched WT controls. Furthermore, when WT aortic
valve cells treated the osteo-differentiation media in the presence of L-NAME, a nitric
oxide synthase inhibitor, calcification was significantly increased compared with controls.
When NOS3-/- aortic valve cells were treated with osteo-differentiation media in the
presence of DETA-NO, a nitric oxide donor, calcification was significantly decreased
compared with controls. Finally I showed that the mRNA expression of Notch1 was
significantly decreased in the NOS3-/- mice and Runx2 mRNA levels were significantly
increased in NOS3-/- mice compared with WT controls. These results were expected since
Notch1 represses the activity of Runx2 in normal aortic valves.7, 8 Taken together, my
study suggests that NOS3 plays a crucial role in the normal maintenance of aortic valves
during adulthood and aging.
In summary, I have demonstrated a crucial role of NOS3 in normal heart
development and in the maintenance of postnatal aortic valve function. More specifically,
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I showed that NOS3 is required for coronary artery development and deficiency in NOS3
leads to hypoplastic coronary arteries. Next, I showed that NOS3 promotes endocardial
EMT and the formation of AV valves during embryonic heart development. Finally, I
showed deficiency in NOS3 results in thrombosis formation and calcification of aortic
valves, suggesting an important role of NOS3 in maintaining normal function and
morphology of aortic valves. A summary of these findings and previous work using
NOS3-/- mice is shown in Figure 5.2. My studies may provide important information for
developing novel therapeutic strategies for the treatment of congenital heart disease and
adult valvular disease.
5.2

STUDY LIMITATIONS

5.2.1 Mouse Models of Human Disease Conditions
Genetically modified mice used as models of human disease conditions are
necessary in the evaluation of potential therapeutics for both ethical and practical reasons.
The use of mouse models allows for the collection of tissue samples, and the control of
experimental conditions that are otherwise not possible in humans. Over 99% of all
mouse genes can be traced to a human homologue thus providing a genetic
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Figure 5.1 Proposed signaling pathway of NOS3 on coronary artery development,
atrioventricular valve formation and adult aortic valve maintenance. NOS3 promotes the
expression of Wt1, Gata4, TGFβ, BMP2 and Notch1 via cGMP. Wt1 and Gata4 promote
coronary artery development via EPDC migration and growth factor signalling,
respectively. TGFβ and BMP2 regulate AV valve formation via activation of Snail1 and
EMT in the endocardial cushion. Finally, Notch1 expression inhibits Runx2 and prevents
adult aortic valve calcification. Lack of NOS3 induces endothelial activation and
thrombosis of aortic valves in aging.
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Figure 5.2 Summary of the biological effects of NOS3 on the heart during embryonic
development and postnatal life.
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system that correlates well with the human genome.9 Finally, the mouse genome is
relatively easy to manipulate and this provides an enormous amount of possibilities for
genetic modification to study various human related diseases.10
This thesis utilized a variety of in vitro and in vivo experimental models to
simulate human heart disease. In vivo, Chapters 2 and 3 used a neonatal mouse model to
study the role of NOS3 in coronary artery development and atrioventricular valve
formation. Chapter 4 used an adult mouse model to study the role of NOS3 in the
normal maintenance of the aortic valves. In humans, NOS3 polymorphisms with reduced
enzyme activity have been shown to be correlated with congenital heart disease and
coronary artery disease.11 In my studies, deficiency in NOS3 expression results in
congenital heart defects including malformations of coronary arteries and impaired
atrioventricular valve development (Chapters 2 and 3) and adult aortic valve thrombosis,
stenosis and calcification (Chapters 4). Previous studies from our lab also showed
deficiency in NOS3 results in congenital heart defects such as atrial and ventricular septal
defects.12 Whole-body knockout animals and the genetic mutation or polymorphisms in
human disease may not be directly comparable. In humans polymorphisms of NOS3 have
been associated with congenital heart disease and coronary artery disease.11, 13-15 These
polymorphisms represent a reduction in the enzyme activity, not a complete deletion of
NOS3. Therefore we would expect the severity of the phenotypes to be much greater in
the animal models. Indeed, in our NOS3-/- mice, up to 80% of offspring dies within the
first 5 days of life compared with the polymorphisms seen in humans which has not been
associated with postnatal mortality.12 Next, even though in this case the phenotypes in
NOS3-/- animals are similar to humans, it is not certain that these phenotypes are a
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primary defect caused by the deficiency of NOS3 in the heart. For example, it is possible
that whole-body knockout of NOS3 leads to changes in other organ systems and through
these changes causing a secondary effect on the heart leading to congenital heart disease.
To address this issue, we have generated a cardiac-specific NOS3 transgenic mouse under
the control of -myosin heavy chain promoter. Expression of human NOS3 was detected
only during embryonic development and specifically in the heart of NOS3Tg mice. The
NOS3Tg mice were then crossed with NOS3-/- to create the NOS3Tg;NOS3-/- mouse, an
animal that lacks NOS3 in all organs except the heart during embryogenesis. cGMP, a
critical downstream signaling molecule of NOS3, was significantly decreased in the
NOS3-/- compared with WT hearts at postnatal day 0 (P0). This animal model allowed use
to study the effect of NOS3 specifically in the heart and our data support an important
role of myocardial NOS3 in embryonic heart development.
For in vitro cell cultures, we isolated ventricular myocytes and epicardium
derived cells (Chapter 2) and cushion cells (Chapter 3) from the embryonic hearts. We
also isolated aortic valve tissues from the hearts of adult mice (Chapter 4). The use of in
vitro cultures presents a problem as these cells may, under certain circumstances, respond
differently than in vivo conditions. For example, the fact that in vivo ventricular myocytes
are under the constant nourishment from the blood supply as well as its physical and
biochemical interaction with surrounding environment simply cannot be duplicated in
any in vitro cultures. In my studies, these cultures were used to overcome technical
barriers in vivo. When studying the developing heart or a very specific tissue in the adult
heart (aortic valves), in vivo manipulations of the tissue of interest is simply not
technically possible. Therefore, we have to employ methods of in vitro culturing to
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delineate the role of NOS3 in these tissues. Notably, our in vitro delineation of
mechanisms has provided new insights on the pathogenesis of phenotypes in the NOS3-/mice.
In summary, this thesis utilized transgenic and knockout mouse models to study
the role of NOS3 in embryonic heart development and in maintaining normal aortic
function during postnatal life. However, murine research also has inherent limitations in
that the mouse heart is different from the human heart. For example the mouse heart beats
approximately 7 times faster and 250 times smaller than the adult human heart. The most
important differences in cardiac structure of human and mouse are confined to the atria.
In the mouse, unlike the human counterpart, there is no extensive formation of a
secondary atrial septum.16 Thus, the relevance of any NOS3-mediated effects described in
this thesis ultimately needs to be confirmed in humans.
5.2.2 Use of Pharmacological Inhibitors to Delineate Signaling Pathways
In Chapter 2 and 3 of this thesis, I used nitric oxide donors DETA-NONOate, as
well as nitric oxide inhibitors such as L-NAME. These agents are easy to use, and have
previously been shown to be effective in increasing or decreasing the availability of NO
to cells. DETA-NONOate belongs to the family of diazeniumdiolates that release low
levels of NO spontaneously at physiological conditions.17 The half-life of DETANONOate under physiological pH is approximately 20 hours and therefore, it is a slow
acting prolonged NO donor that mimics NOS3 when given at low μM concentrations.18
L-NAME is an analogue for L-arginine. It competes with L-arginine for the substrate
binding site on NOS. However, unlike L-arginine, L-NAME cannot be converted to Lcitrulline and therefore NO production is inhibited.19 Although L-NAME is considered a
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non-selective NOS inhibitor, it appears to have a higher selectivity to NOS3 than
iNOS.20, 21 Therefore, the choices of the nitric oxide donor and inhibitor are based on the
understanding of their functions, and studies using these agents to ensure proper dosing
and selectivity. However, as is the case with all pharmacological compounds, I cannot
rule out the non-specific effects of the pharmacological agents. For example, L-NAME (2
µM) can also inhibit the production of prostaglandins and interleukin-1 beta.20, 21 In my
studies, I used pharmacological agents as a secondary verification of genetic
manipulations such as genetically altered mice. Thus I am confident that the results I
obtained are indeed due to alterations of NO levels rather than non-specific effects of
these agents.
5.3

SUGGESTIONS FOR FUTURE RESEARCH
The novelty of this thesis is the demonstration that NOS3 is crucial in the

developing heart and maintenance of adult aortic valve function. However, there are
many valuable aspects of the role of NOS3 during development still warrant further
investigation.
In Chapter 2, I observed that NOS3 deficiency leads to coronary artery
malformations. Coronary artery development involves many complex highly regulated
steps. The epicardium first undergoes epithelial-to-mesenchymal transition (EMT) and
gives rise to epicardium-derived cells (EPDCs), which migrates into the myocardium to
form smooth muscle cells and fibroblasts that are essential for the development of
coronary arteries.22-24 Recent clonal analysis confirmed earlier studies in avian embryos
that the endothelium of the coronary vascular system derives from endothelial sprouts of
sinus venosus with a minor contribution from the endocardium.25-27 Thus, endothelial
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cells from sinus venosus and endocardium, and vascular smooth muscle cells and
fibroblasts derived from EPDCs contribute to the formation of coronary arteries.
Coronary artery development is further divided into major coronary artery development,
coronary artery capillary vessel development and coronary vessels connection to the aorta.
In this thesis and previous studies from our lab showed deficiency in NOS3 leads to
major coronary artery malformations and decreased coronary capillary vessels
development. However, we did not look at the role of NOS3 in the connection of
coronary vessels to the aorta. In humans and mice, many coronary artery anomalies can
occur.28-30 For example, both left main and right main coronary artery are connected to
the same sinus of Valsalva of the aorta.29, 30 Whether a disruption of NOS3 mediates the
abnormal connection of coronary arteries to the aorta is an interesting area to pursue for
future studies.
In addition to studying the role of NOS3 in coronary artery development, one
potential project could look at other vascular development in the body. There are major
similarities in vessel development in the developing embryo. For example, it has been
shown lungs of NOS3-deficient mice also exhibit a paucity of distal arteriolar branches
and capillary hypoperfusion, which resemble alveolar capillary dysplasia in humans.31
The finding is consistent with the role of NOS3 in capillary development and
angiogenesis.32, 33
Additionally, during development of the cardiac conduction system, Purkinje
fibers receive paracrine cues from developing coronary vessels.34,

35

Inhibition of

coronary artery development decreases Purkinje fiber differentiation suggesting that
coronary arteries are necessary and sufficient for the induction of Purkinje fibers.34 Thus,
176

it is possible that coronary artery defects in NOS3-/- mice may impede the development of
the cardiac conduction system.

34, 35

Whether lack of NOS3 impairs development of

cardiac conduction system remains to be investigated.
In Chapter 3, I demonstrated that deficiency in NOS3 leads to congenital
atrioventricular valve insufficiency and severe atrioventricular valve regurgitation. They
only represent 2 of the 4 valves involved in the regulation of blood flow in the developing
heart. The other 2 valves are aortic valve, which controls the blood flow between the left
ventricle and outflow aorta and pulmonary valve, which controls the blood flow between
the right ventricle and outflow pulmonary artery. Previous study showed the deficiency in
NOS3 results in bicuspid aortic valve formation, which is a congenital malformation with
only 2 instead of 3 valve leaflets. However, that study did not assess the development of
the pulmonary valves. Bicuspid pulmonary valves are extremely rare and are often
associated with other congenital cardiac defects. Isolated bicuspid pulmonary valve is
exceedingly rare condition. Because of the extremely rare occurrence of bicuspid
pulmonary valve, this condition is often under studied. Therefore, it is worthwhile to look
at the role NOS3 in the development of pulmonary valves and to assess whether
deficiency of NOS3 results in the formation of bicuspid pulmonary valves.
In Chapter 4, I showed that deficiency of NOS3 leads to calcified aortic valve
stenosis. I demonstrated phenotypes of aortic valve regurgitation, stenosis, thickening and
calcification of the valves. In the clinic, later stages of untreated calcified aortic valve
stenosis are associated with left ventricular hypertrophy and eventually heart failure.
Unfortunately we did not see these phenotypes in the 12 months NOS3-/- animals. It
would be interesting to study these animals at 18 or 24 months to see if they develop left
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ventricular hypertrophy and heart failure. In addition, it would be interesting to see the
condition of others valves in these aged mice. More specifically, the function of the
pulmonary, mitral and tricuspid valves can be assessed to see if these phenotypes are
limited to the aortic valves or it may apply to all valves within the aging heart.
5.4

CLINICAL APPLICATION
Over the past decade, mutations and polymorphisms of the NOS3 gene have been

identified in association with coronary artery disease.13-15 In addition, a recent study
showed the common G894T polymorphism, which has reduced NOS3 function, is also a
risk factor for congenital heart disease.11 This finding is consistent with the role of NOS3
in heart development in mice.12, 36, 37 Taken together, these findings help to establish a
critical role of NOS3 in early heart development in both humans and mice. The present
thesis showed for the first time a critical role of NOS3 in the developing heart and in the
maintenance of adult aortic valve functions. Along with our current understanding of
NOS3 mutations and polymorphisms as a risk factor, reduced NOS3 function not only
puts individuals at higher risk of developing coronary artery disease and congenital heart
disease,4, 11, 13-15 but may also affect embryonic coronary artery development,
atrioventricular valve development and aortic valve dysfunction and calcification in the
next generation through heritable mutations and polymorphisms in the NOS3 gene.
Furthermore, we propose individuals with heritable mutations and polymorphisms in the
NOS3 gene may be at risk for HCAD, atrioventricular valve insufficiency and calcified
aortic valve stenosis. We anticipate that these new insights into the mechanisms of
coronary artery development, atrioventricular valve development and maintenance of
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adult aortic valve function may lead to therapeutic strategies in the prevention and
treatment of congenital heart disease and adult valvular disease.
5.5

CONCLUSIONS
This thesis provides the first evidence that NOS3 is crucial in the development of

the coronary artery, the formation of atrioventricular valves and the adult maintenance of
aortic valve function. While further investigation is required to determine the therapeutic
potential of NOS3 in the treatment of HCAD, atrioventricular valve insufficiency and
calcified aortic valve stenosis, it is clear that NOS3 is required in the development heart
as well as normal valvular function in the adult. Furthermore, this work has provided
valuable insight into the mechanisms by which NOS3 is involved in coronary artery
development (Chapter 2), formation of the atrioventricular valves (Chapter 3) and
maintenance of adult aortic valve function (Chapter 4). Overall my doctoral research has
broadened our understanding of NOS3 in the developing heart and regulation of normal
adult valvular function, and may contribute to the development of therapeutics for the
treatment of HACD, atrioventricular valve insufficiency and calcified aortic valve
stenosis.
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